



Published in final edited form as:

Adv Ophthalmol Pract Res. 2021 November ; 1: . doi:10.1016/j.aopr.2021.100005.

Potential underlying genetic associations between keratoconus and diabetes mellitus

Kristin M. Ates^{a,b}, Amy J. Estes^{b,c}, Yutao Liu^{a,c,d,*}

^aDepartment of Cellular Biology and Anatomy, Medical College of Georgia, Augusta University, Augusta, GA, USA

^bDepartment of Ophthalmology, Medical College of Georgia, Augusta University, Augusta, GA, USA

^cJames and Jean Culver Vision Discovery Institute, Medical College of Georgia, Augusta University, Augusta, GA, USA

^dCenter for Biotechnology and Genomic Medicine, Medical College of Georgia, Augusta University, Augusta, GA, USA

Abstract

Background Keratoconus (KC) is the most common ectatic corneal disease, characterized by significantly localized thinning of the corneal stroma. Genetic, environmental, hormonal, and metabolic factors contribute to the pathogenesis of KC. Additionally, multiple comorbidities, such as diabetes mellitus, may affect the risk of KC. Main Body Patients with diabetes mellitus (DM) have been reported to have lower risk of developing KC by way of increased endogenous collagen crosslinking in response to chronic hyperglycemia. However, this remains a debated topic as other studies have suggested either a positive association or no association between DM and KC. To gain further insight into the underlying genetic components of these two diseases, we reviewed candidate genes associated with KC and central corneal thickness in the literature. We then explored how these genes may be regulated similarly or differentially under hyperglycemic conditions and the role they play in the systemic complications associated with DM. Conclusion Our comprehensive review of potential genetic factors underlying KC and DM provides a direction for future studies to further determine the genetic etiology of KC and how it is influenced by systemic diseases such as diabetes.

This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

*Corresponding author. 1460 Laney Walker Blvd, CB1101, Augusta, GA, 30912, USA. yutliu@augusta.edu (Y. Liu).

Author contribution

Kristin M. Ates: Methodology, Investigation, Writing – Original Draft, Writing Review & Editing, Amy J. Estes: Writing Review & Editing, Yutao Liu: Conceptualization, Writing Review & Editing, Supervision, Funding Acquisition.

Ethics approval and consent to participate

Not applicable.

Declaration of interest

None for all the authors.

Study approval

Not Applicable.

Keywords

Keratoconus; Genetics; Diabetes; Collagen crosslinking; Oxidative stress

1. Introduction

Keratoconus (KC) is a bilateral, progressive ectatic corneal disorder characterized by localized thinning of the corneal stroma and alteration of corneal curvature.¹ As the cornea adopts a conical shape, this results in myopia, irregular astigmatism, and eventual visual impairment.¹ The histopathology of KC includes stromal thinning, breaks in Bowman's layer, focal fibrosis, thickening of the epithelium, and keratocyte apoptosis in the anterior stroma.^{2,3} Although KC is known to be multi-factorial with genetic, metabolic, hormonal, and environmental influences, the exact etiology remains elusive.⁴⁻⁶ The risk of developing KC has been associated either positively or negatively with many systemic disorders, including but not limited to, Down syndrome,⁷ connective tissue diseases,⁸⁻¹⁰ autoimmune diseases,¹¹ and diabetes mellitus (DM).^{9,12-15} However, the exact etiology of KC and its relationship to systemic diseases, such as DM, remains elusive.

DM may have multiple effects on the cornea, including keratopathy, neuropathy, inflammation, alterations in collagen fibrils, and endothelial cell loss.¹⁶ Multiple studies have suggested that DM is inversely associated with the risk of KC, suggesting a protective role against the development and/or severity of KC.^{13,14,17,18} This is in contrast to other studies that have reported either 1) a positive association in both prevalence and severity between KC and DM or 2) no significant correlation between the two diseases.^{14,19-22} This discrepancy may be reflective of the varying sample sizes, inclusion/exclusion criteria, sample ascertainment approaches, and populations analyzed (Table 1).

Our goal was to provide a comprehensive review of potential genetic associations between DM and KC. We have outlined various genes implicated in KC risk and summarized their potential roles in DM-induced corneal changes (Table 2). These genes may work through several mechanisms including alterations in corneal biomechanics and collagen crosslinking, alterations in ECM composition and proteolytic activity, as well as increased inflammation and oxidative stress.

2. Clinical significance

By gathering information regarding the potential overlapping genetic factors in KC and DM, this review discusses potential therapeutic targets that may slow or halt the progression of KC. In other words, it might be beneficial to manage KC by utilizing the same mechanisms that strengthen the cornea in DM. These mechanisms include but are not limited to shifting the balance in the cornea microenvironment towards increased endogenous collagen crosslinking, decreased extracellular matrix (ECM) remodeling and proteolytic degradation, and decreased inflammation. By regulating local gene expression, this may serve as an alternative form of therapy for those patients in which corneal crosslinking is not an option, such as those with prior history of herpetic keratitis and history of poor epithelial wound

healing.²³ Furthermore, this may reduce the need for corneal transplantation in patients with more severe forms of KC.

3. Corneal biomechanics and collagen crosslinking in KC and DM

The cornea is naturally a viscoelastic structure, in that it must be elastic enough to expand into an aspheric half-sphere, but stiff enough to maintain its shape and resist the intraocular pressure (IOP).^{24,25} There is a delicate interplay between the multiple corneal layers and the composition within each layer that contributes to the overall corneal shape. This involves the organization of the collagen structure within each layer, the attachment of proteoglycans and glycosaminoglycans to collagen fibers, the corneal swelling pressure, and the production/ degradation of extracellular matrix components.²⁴ There are three major mechanisms of collagen crosslinking important in corneal biology, as previously outlined in McKay et al., 2019.²⁶ Those include an enzymatic reaction: lysyl oxidase-mediated crosslinking as well as two non-enzymatic reactions: 1) advanced glycation end product (AGE)-mediated crosslinking and 2) photooxidative crosslinking mediated by riboflavin as a treatment option for KC. We will discuss the crosslinking mechanisms in more detail as they relate to the genes involved in KC and DM.

In order to quantify differences in corneal shape and structure, two measurements are commonly obtained: the central corneal thickness (CCT) and corneal hysteresis (CH). While CCT is a gross measure of the overall thickness of the cornea, CH reflects the viscous damping ability of the cornea. CH combines elasticity and viscosity and provides further information on the structural integrity of the cornea. Increased edema in the cornea may give the appearance of stromal thickening and increased CCT. This must be taken into account in systemic diseases such as DM, in which glucose induces increased water retention in multiple tissues, including the cornea.^{27,28}

KC is associated with alterations in the corneal biomechanics.¹ Previous studies have shown altered expression or abnormal localization of extracellular matrix (ECM) components in KC,²⁹ with decreased levels of proteoglycan core proteins and abnormal collagen synthesis.²⁵ Furthermore, age has been shown to be inversely correlated with the risk of KC³⁰ and KC progression,³¹ suggesting that age-related crosslinking is protective against KC and other ectasias.³²

Conversely, diabetes is known to be an independent cause of endogenous, non-enzymatic crosslinking as high levels of glucose causes glycosylation of corneal fibers and increases AGE-mediated crosslinking in the cornea, causing the cornea to become stiffer.^{13,32-34} As a result, increased CCT and alteration in corneal endothelial cells have been observed in patients with diabetes.³⁵⁻³⁹ Lee et al., 2006 reported that CCT was significantly correlated with the duration of diabetes after controlling for age.³⁷ Interestingly, Hager et al., 2009 observed a significant increase in CH in patients with diabetes, although they did not observe a significant increase in CCT after correcting for age, IOP, and gender.⁴⁰ Schler et al., 2012 also reported significantly higher CH and corneal resistance factor (CRF) in patients with poorly-controlled diabetes as compared to healthy subjects and well-controlled diabetes.⁴¹ Since CH and CRF are correlated to HbA1c, this suggests that the cornea

biomechanics could be altered depending on extent of glucose control.⁴¹ These findings suggest that DM may induce structural alterations in the cornea. In terms of corneal biomechanics, in this section we discussed two genes, *LOX* and *COL5A1*, and their roles in relationship to the corneal biomechanics observed in KC and DM.

3.1. LOX

Lysyl oxidase (LOX) is a copper amine oxidase that initiates the physiologic crosslinking of collagens and elastin by oxidizing the side chain of peptidyl lysine, thus generating reactive aldehydes on lysine residues that may cross-react with nearby groups.^{26,42,43} In the eye, the LOX enzyme has been detected in the trabecular meshwork, ciliary body, lens, retina, and cornea.⁴⁴⁻⁴⁶ In addition to LOX, there are four LOX-like proteins (LOXL1, LOXL2, LOXL3, and LOXL4) that also catalyze the oxidative deamination of lysine residues in collagen and elastin⁴⁵.

Multiple genome-wide association studies (GWAS) and candidate association studies have identified the association between sequence variants in *LOX* to both KC risk and CCT, suggesting its potential role in KC pathogenesis.⁴⁷⁻⁴⁹ Specifically, a particular SNP rs2956549 in *LOX* has been associated with KC in various ethnicities as well as a meta-analysis.⁵⁰⁻⁵³ Dudakova et al., 2012 reported altered distribution of LOX expression in the corneal stroma of KC patients, with a reduction in total LOX (both LOX and LOXL) protein activity in corneal fibroblasts derived from KC corneas.⁴⁵ This was consistent with a recent study that reported reduced pre-existing LOX and collagen levels in a patient who developed ectasia after small incision lenticule extraction (SMILE), despite normal preoperative biomechanical evaluation.⁵⁴ Furthermore, ectopic LOX expression in the human corneal fibroblast induced significantly more collagen gel contraction *in vitro*, confirming the role that it plays in strengthening the corneal stroma.⁵⁴

Given LOX's role in collagen crosslinking, reduced LOX activity in KC may lead to impaired cross-linking which results in corneal ectasia.^{45,54} Although there is a confirmed genetic association of LOXL1 to pseudoexfoliation syndrome and open-angle glaucoma,^{46,55,56} it is still unclear the role that LOXL proteins may play in the cornea. Dudakova et al., 2016 confirmed that LOXL1-4 enzymes were present in all layers of the cornea in cryosection samples and reported lower LOXL2 expression in KC corneas using IHC and Western blot analyses.⁵⁷ Further studies will be required to better understand the expression patterns and activity of LOXL proteins in the cornea.

The exact role of LOX in DM-induced corneal changes remains unclear, as one study failed in observing an increase in LOX-mediated crosslinking in the cornea of DM patients.³³ However, Chronopoulos et al., 2010 revealed that hyperglycemic conditions increased LOX expression and LOX activity in rat retinal endothelial cells *in vitro* and in diabetic rat retinas *in vivo*.⁵⁸ This is consistent with the finding of increased LOX-dependent crosslinking in skin collagen in patients with diabetes.⁵⁹ Coral et al., 2013 confirmed increased LOX mRNA expression in ARPE-19 cells exposed to high glucose.⁶⁰ Further studies will be required to investigate the effects of DM on LOX activity in the cornea. The increase in LOX activity and expression in response to high glucose in retinal studies suggests that high glucose may have a similar effect in corneal stromal and endothelial cells. Given that the cornea is an

avascular structure, there may be differential upstream regulation of *LOX* in response to high glucose concentrations as compared to the retina.

3.2. COL5A1

Since collagen is the most abundant protein in the cornea,²⁶ it is not surprising that various types of collagen have been implicated in association with CCT and KC, including COL1A1 and COL1A2,⁶¹ COL8A2,⁶² and COL5A1.^{37,63} The genetic association of COL5A1 with CCT, in particular, reached genome-wide significance after combining data from European, Australian, and Singaporean GWAS.^{62–66} Collagen type V is a regulatory fibril-forming collagen involved in the formation of heterotypic fibrils with collagen type I.^{67–70} Together, both collagen type I and V are the dominant collagen isoforms in the human corneal stroma.⁷¹ Although collagen type V only comprises 2–5% of the total collagen in most tissues, it determines 10–20% of the fibrillary collagens in the cornea.^{67,72} Interestingly, the most common molecular mechanism in classic Ehler-Danlos syndrome (EDS), a generalized connective tissue disorder, is a functional loss of one COL5A1 allele.^{73,74} Segev et al., 2006 investigated the corneal phenotype in EDS patients with *COL5A1* haploinsufficiency and *Col5a1*^{+/-} mouse models. Both EDS patients and knockout mice exhibited consistent corneal thinning and the *Col5a1*^{+/-} mice also exhibited a decrease in total collagen content with a 25% reduction in the number of stromal fibrils.⁷² These findings suggest that alterations in *COL5A1* expression serves as a strong genetic predisposition towards the development of corneal thinning and KC.

In DM, collagen is influenced by hyperglycemia primarily through nonenzymatic AGE-mediated crosslinking. This occurs by way of the Maillard reaction, in which a primary amine found on amino acid residues, such as lysine or arginine, is converted to a reactive Schiff base that rearranges to form the Amadori product.²⁶ This serves as an early-stage product that leads to the formation of AGE products. A classic example of the Maillard reaction is the glycation of hemoglobin, which gives rise to the glycated HbA1c, the established biomarker for sustained glucose levels.^{26,75} Studies have identified increased end products of the Maillard reaction, including pentosidine, within the diabetic cornea.^{26,33} This increase in AGE-mediated crosslinking in DM has been associated with increased tendon stiffness and higher mechanical strength, which could be inhibited by insulin supplementation.^{26,76,77} As a result, the increased crosslinked collagen is resistant to enzymatic degradation in the cornea.⁷⁸ AGE-mediated crosslinked adducts can then bind to the receptor for advanced glycation end products (RAGEs), which are pro-inflammatory receptors expressed in a wide variety of tissues. Although originally described for its ability to bind AGEs, RAGEs have the capability to bind multiple other ligands and play a crucial role in homeostasis and inflammatory processes.^{79,80}

To our knowledge no direct associations between *COL5A1* expression and DM have been established. Very recently, Ng et al., 2020 evaluated possible gene-environment interactions between genetic variants identified via GWAS, and the effect of glycemic control (indicated by HbA1c) on the risk of severe diabetic retinopathy (DR).⁸¹ Interestingly, the SNP *COL5A1* rs59126004 exhibited a protective effect against DR in patients with adequate glycemic control (HbA1c <7%), but not in patients with inadequate glycemic control

(HbA1c $\geq 7\%$),⁸¹ suggesting a potential interaction between *COL5A1* rs59126004 and glucose levels in the retina.

Priyadarsini et al., 2016 quantified the expression of collagen type I, III, and V in the human corneal stroma of Type 1 and Type 2 DM, and discovered elevated levels of collagen type I and type III, but not collagen type V.²⁷ Given that this was a small study with four to eight donor corneas in each category, it would be worth expanding the study with a larger sample size. Collagen type I and V are the predominant types of a healthy cornea, while collagen type III is primarily associated with fibrosis and wound healing in the setting of injury. This finding suggests that hyperglycemia may induce collagen expression in an isoform-dependent manner.²⁷ We expect more studies of *COL5A1* to better understand DM's direct effects on *COL5A1* in the cornea.

4. Alterations in extracellular matrix (ECM) remodeling in the cornea

In line with collagen crosslinking, alterations in corneal ECM remodeling have been observed in KC and DM including variations in cellular proliferation, disruption in autophagic flux, and increased ECM fibrosis. This is complemented by the observation of an imbalance between matrix metalloproteinase (MMP) and tissue inhibitors of matrix metalloproteinase (TIMPs) in KC patients.^{82,83} Here, we take a close look at several KC and CCT-associated transcription factors including *FOXO1*, *SMAD3*, *TGFBI*, and *ZEB1* (Table 2). We then searched the literature to determine how they may be differentially regulated under hyperglycemic conditions in the cornea. We also included ECM remodeling genes *MMP-9*, *TIMP-1*, and *MIR184*.

4.1. FOXO1

Transcription factor Forkhead box protein O1 (FOXO1) is ubiquitously expressed in mammalian cells.⁸⁴ It mediates multiple different pathways, including regulation of metabolic homeostasis, oxidative stress, cell proliferation, and autophagy. Sequence variants near or within *FOXO1* have been associated with CCT,^{66,85,86} but its effect on FOXO1 expression and activity is not well-described in the KC cornea. FOXO1 is regulated by a variety of environmental factors, including insulin, which normally inhibits FOXO1 activity.⁸⁷ In settings of insulin resistance and increased glucose, such as T2DM, increased FOXO1 has been shown to induce gluconeogenesis abnormalities, cell apoptosis, uncontrolled autophagy, and inhibition of proliferation.^{84,88}

Although much remains to be understood about FOXO1's role in KC and DM, some studies have analyzed its effects on vascular endothelial cells. Wilhelm et al., 2016 indicated that FOXO1 decreases the metabolic and proliferative activities of vascular endothelial cells by attenuation of glycolysis and mitochondrial respiration.^{84,89} This study reported that the endothelial-restricted deletion of FOXO1 in mice caused a profound increase in endothelial cell proliferation, such that it induced vascular hyperplasia and vessel enlargement. In contrast, overexpression of FOXO1 resulted in vessel thinning and reduced branching of vasculature.⁸⁹ A separate study reported that FOXO1 signaling was involved in AGE-induced vascular endothelial cell autophagy through impairment of autophagosome-lysosomal fusion. This impaired autophagic flux then resulted in endothelial cell autophagic

apoptosis.⁹⁰ These findings are intriguing as they suggest a correlation in FOXO1 activity with AGE-induced endothelial damage and decreased endothelial cell proliferation in the vasculature. Thus, it would be interesting to perform similar studies in the microenvironment of the cornea to determine if differential regulation of FOXO1 may contribute to altered endothelial cell proliferation and/or endothelial cell apoptosis in KC and DM corneas.

4.2. SMAD3

There are three functional classes of SMAD proteins, including the receptor-regulated SMAD (R-SMAD), the Co-mediator SMAD (Co-SMAD), and the inhibitory SMAD (I-SMAD) proteins.⁹¹ SMAD3 is an R-SMAD that is directly phosphorylated and activated by type I receptor kinases, forming activated SMAD complexes that then activate the transcription of target genes,⁹¹ specifically those involved in the TGF β signaling pathway. TGF β signaling is tightly regulated by I-SMAD proteins, SMAD6 and SMAD7, which compete for binding of SMAD3 to co-mediators.⁹² TGF β signaling is known to play an important role in ECM remodeling and MMP expression.^{93–95}

Several studies have identified involvement of TGF β signaling in KC.^{96–99} Priyadarsini et al., 2015 observed a significant increase in pSMAD3 expression with TGF β 3 signaling in human KC cells compared to normal human corneal fibroblasts.⁹⁸ This was paralleled by significant downregulation of SMAD6/7 at baseline and failure of SMAD6/7 upregulation in response to stimulation with TGF β in the human KC cells.⁹⁸ Recently, variants near or within *SMAD3* were identified to be associated with KC susceptibility in GWAS of CCT,^{49,100} further reinforcing its potential role in KC pathogenesis. Taken together, it has been suggested that the lack of inhibition by SMAD6/7, along with potential alterations in SMAD3 activity, results in increased TGF β signaling that may promote the formation of a fibrotic ECM in KC.⁹⁸

TGF β /SMAD signaling plays an important role in regulating glucose and energy homeostasis as well.¹⁰¹ The TGF β /SMAD3 pathway is activated downstream of the AGE/RAGE signaling pathway in the setting of hyperglycemia.^{102,103} This is suggested to be the main driving force in the development of diabetic nephropathy (DN) due to increased ECM deposition in mesangial cells.^{104,105} Ono et al., 2018 demonstrated that AGE stimulation resulted in significant activation of Smad1 and Smad3 in mesangial cells in mice, likely as a result of increased TGF β signaling.¹⁰⁶ Additionally, the loss of Smad3 prevented renal dysfunction under diabetic conditions by reduced mesangial matrix accumulation and reduced GBM thickening.¹⁰⁶ This reinforces the critical role that TGF β /SMAD3 plays in ECM remodeling, and shows that this pathway is also affected under hyperglycemic conditions. However, this pathway has not been analyzed in the DM cornea. Interestingly, TGF β /SMAD3 signaling promoted gluconeogenesis in hepatocyte cells through interaction with FOXO1, another established KC-susceptibility gene.¹⁰¹ It is necessary to determine if the TGF β /SMAD interaction with FOXO1 is present in the human cornea.

4.3. TGFBI

The transforming growth factor beta-induced (*TGFBI*) gene has been implicated in the pathogenesis of KC and a heterogeneous group of corneal dystrophies that are characterized

by the progressive loss of corneal transparency.¹⁰⁷ It encodes transforming growth factor beta-induced protein (TGFBIp), which is also known as keratoepithelin, BIGH3, or β igh3.¹⁰⁸ In the cornea, it is expressed primarily in the corneal epithelium, stroma, and retrocorneal fibrous membranes.^{108–112} TGFBIp is known to interact with multiple extracellular macromolecules, including the proteoglycan decorin¹¹³ and collagen type I, II, IV, VI, and XII.^{114–117} It is thought to link cells to the ECM through various integrin binding sites^{116,118–122} and thus play important roles in corneal wound healing and maintenance of the ECM.

In a cDNA library constructed from KC corneas, *TGFBI* was found to be the second most abundant transcript.¹²³ Sequence variants in *TGFBI* were also identified in Chinese and Polish KC patients.^{124,125} However, the exact relationship between *TGFBI*, TGFBIp, and KC is still unclear. Researchers have suggested that mutations in *TGFBI* could contribute to decreased mechanical stability in the cornea, thus resulting in corneal thinning as seen in KC.¹²⁶ This is supported by findings of decreased TGFBIp in KC corneas.¹²⁶ Conversely, elevated levels of TGFBIp have been found in areas of corneal scarring, likely due to TGFBI-mediated upregulation in response to corneal injury.^{126–128} Interestingly, two KC patients had stromal amyloid deposits that were associated with TGFBIp in the corneal buttons, but no *TGFBI* mutation was present.⁹⁹ It is possible that there was concurrent scarring in these two patients, or that local factors in the KC corneas predispose to development of TGFBIp amyloid deposits, thus disrupting the structural integrity of the cornea.⁹⁹

TGFBI has also been identified as a potential risk gene for the development of both T1DM and T2DM after detecting the association of several SNPs in human genetic studies.¹²⁹ Aside from the cornea, TGFBIp is produced by smooth muscle cells, fibroblasts, and proximal tubular epithelial cells^{130,131} upon TGF β or high-glucose stimulation.^{127,132} In studies investigating DM, it was observed that high glucose levels increased TGFBIp expression in renal proximal tubule epithelial cells by activating TGF β . This coincided with findings of a high glucose-stimulated increase in collagen and fibronectin production in mesangial cells and proximal tubular cells, which is mediated by TGF β activation.^{133–135} Although the pathologic consequences of increased TGFBIp in the proximal tubules remains unclear, it may play an important role in the degree of renal interstitial fibrosis, which is closely correlated with a progressive decline in renal function in DM.^{132,136,137} To date, no studies have analyzed *TGFBI* and TGFBIp in the diabetic cornea, but TGFBI has been shown to be upregulated *in vitro* in the human corneal epithelial cell line in response to TGF β .¹²⁸ Given these findings, it is possible that TGFBIp may also be increased in the cornea in response to high glucose, promoting TGF β -mediated corneal thickening and fibrosis. Additionally, it has been suggested that TGFBIp mutations occur in a genotype-phenotype fashion, in which various mutations account for the different degrees of phenotypic severity seen in KC and corneal dystrophies.¹³⁸ Thus, the high glucose environment seen in DM could result in a variation on the phenotypic spectrum of *TGFBI* mutations and/or epigenetic modifications.

4.4. ZEB1

The zinc finger E box-binding homeobox 1 (*ZEB1*), also known as transcription factor 8 (*TCF8*)^{139,140} or δ EF1,¹⁴¹ can function as either a transcriptional enhancer or repressor for different genes.¹⁴² *ZEB1* has been implicated in the regulation of type 1 collagen expression, particularly in osteoblasts,¹⁴¹ and repression of the epithelial phenotype.^{140,143,144} It has been identified as a potent epithelial to mesenchymal transition (EMT) activator and stimulator of angiogenesis in tumor biology studies,^{145–147} as well as a regulator of TGF β signaling with its counterpart, *ZEB2*.¹⁴⁸

Mutations in *ZEB1* have been reported in posterior polymorphous corneal dystrophy (PPCD),^{139,140,149} Fuch's endothelial corneal dystrophy (FECD),^{127,150,151} and keratoconus.¹⁵² This highlights another example of genetic heterogeneity that results in a variety of phenotypic presentations, like that of *TGFBI*. A heterozygous frameshift mutation in *ZEB1* was found to induce ectopic expression of *COL4A3* by corneal epithelial cells in PPCD, implicating *COL4A3* as a possible target of *ZEB1* regulation.¹⁴⁰ In contrast, a missense *ZEB1* mutation resulted in markedly reduced *COL4A1*, *COL4A2*, and *COL4A3* expression in corneal keratocytes.¹⁵² Reduced expression of *COL4A1* and *COL4A3* has also been reported in KC,^{29,153} but further work is required to determine the role of *COL4A1*/*COL4A3* and how they may be regulated by *ZEB1* in KC. Based on current findings, Lechner et al., 2013 suggested that missense mutations in *ZEB1* are associated with FECD and KC, while protein truncating mutations result in PPCD.¹⁵² This is supported by the finding of unique mutations in a family with both KC and FECD, as well as a patient with triple corneal dystrophy consisting of KC, FECD, and epithelial basement membrane corneal dystrophy.^{152,154}

In efforts to better understand *ZEB1*'s role in wound healing and angiogenesis, it was recently found that persistent hyperglycemia, as seen in DM, potently induced *ZEB1* expression in human dermal microvascular endothelial cells (HMEC).¹⁵⁵ This corresponded with increased *ZEB1* expression in laser capture microdissection endothelial tissue obtained from the wounded edge of diabetic wound patients.¹⁵⁵ In Singh et al., 2019, immunoprecipitation-mass spectrometry was performed to gain further mechanistic insights into the differential action of *ZEB1* under normoglycemic and hyperglycemic conditions, thus revealing putative proteins that physically associated with *ZEB1*.¹⁵⁵ It was found that hyperglycemia diminished the physical association of *ZEB1* with E-cadherin, resulting in a loss of control over E-cadherin repression which is known to cause the microvascular endothelial dysfunction commonly observed in DM.^{155,156} Additionally, hyperglycemic conditions impaired the binding of several pro-inflammatory proteins, suggesting that alterations in cellular *ZEB1* may contribute to the inflammation seen in DM.¹⁵⁵

A different study analyzed the role of long noncoding RNA (lncRNA) *ZEB1* antisense 1 (*ZEB1-AS1*) in DM, as it has been shown to increase *ZEB1* expression.^{157,158} By increasing *ZEB1* expression, *ZEB1-AS1* is thought to play an antifibrotic role in DM through modulation of EMT, which is considered to be the main pathogenic factor of renal fibrosis.^{158–160} Wang et al., 2018 confirmed this in *ZEB1-AS1* knockdown studies, which increased high glucose-induced ECM accumulation by downregulation of *ZEB1* expression, resulting in renal fibrosis.¹⁶¹ This was investigated further by Meng et al.,

2020, who reported that *ZEB1-AS1* was down-regulated in kidney tissues of DM patients as well as hyperglycemic-induced HK-2 cells.¹⁵⁸ Furthermore, ZEB1-AS1 improved the high glucose-induced EMT and fibrogenesis by mediating miR-216a-5p and BM7.¹⁵⁸ While the exact mechanisms are beyond the scope of this review, it is clear that there is a very complex mechanism of regulation surrounding ZEB1. It is important to study the role of *ZEB1* in the cornea of DM patients as it may have the potential to alter the expression of inflammatory cytokines and disrupt corneal endothelial/epithelial structure under hyperglycemic conditions.

4.5. MMP-9 and TIMP-1

MMPs are a family of 24 zinc-dependent proteases involved in multiple physiological processes including tissue remodeling and the degradation of ECM.^{162,163} The activity of the MMPs is balanced by four inhibitory proteins, the tissue inhibitors of metalloproteinases (TIMPs1–4).^{164,165} Multiple MMPs have been implicated in the pathogenesis of KC, including MMP-1, MMP-2, MMP-3, MMP-7, and MMP-13.^{166,167} MMP-9, also known as gelatinase B, is among the most well-studied in relation to KC.¹⁶⁴ Multiple studies of tear composition have shown increased levels of MMP-9 protein in KC, including one patient with asymmetrical KC in which MMP-9 was upregulated only in the tears of the affected eye.^{168–170} This increase in MMP-9 was confirmed with an accompanying upregulation of *MMP-9* mRNA in the corneal epithelium.¹⁷⁰ Interestingly, the *MMP-9* mRNA in KC patients was significantly higher in cells from the cone apex as compared to the corneal periphery, which may contribute to the focal structural weakness of the cornea.¹⁷¹ An additional study revealed an increase in MMP-9 protein level in the blood of KC patients compared to controls.¹⁷²

TIMP-1 exhibits a unique binding interaction with MMP-9, as it usually exhibits a high level of coordinated expression with MMP-9, is frequently secreted as a TIMP-1/MMP-9 complex, and binds MMP-9 with high affinity.¹⁷³ Recent studies revealed a decrease in the levels of TIMP-1 in KC corneas.^{83,174,175} Taken together, the increased MMP-9 and decreased TIMP-1 activity seen in KC may reflect in an imbalance of proteolytic activity, thus contributing to ECM degradation and corneal thinning. This is reinforced by the analyses of genetic polymorphisms in *MMP-9* and *TIMP-1* in KC patients that were associated with findings of higher MMP-9 and lower TIMP-1 activity in KC tear samples.¹⁷⁶ It is important to note that the *TIMP-1* SNP was only associated with increased KC risk in females.¹⁷⁷ Given that *TIMP-1* is located on the X chromosome,¹⁷⁸ this likely accounts for differences in gender susceptibility.

In regards to DM, studies have indicated that elevated glucose levels also disrupt the MMP/TIMP balance in macrophages and endothelial cells, primarily through an amplification in MMP expression and activity.¹⁷⁹ Takahashi et al., 2000 reported enhanced MMP activity in human corneal epithelial cells under hyperglycemic conditions as well as increased MMP-9 activity in the cornea of diabetic rat models.¹⁸⁰ In support of this finding, two studies reported: 1) increased MMP-9 and TIMP-1 protein levels in the tears of pediatric T1DM patients along with 2) increased MMP-9 activity in tears of T2DM patients.^{181,182} Additionally, genetic polymorphisms in *MMP-9* have been associated with susceptibility to

T2DM and diabetic nephropathy.^{183–185} However, no genetic association has been identified with *TIMP-1* and DM in patients.¹⁸⁵ The role of *TIMP-1* in DM remains inconclusive. Taken together, differences in the imbalance of *MMP-9/TIMP-1* activity may contribute to different degrees of ECM remodeling in the cornea of KC and DM patients.

4.6. MIR184

MicroRNAs (miRNAs) bind to the complementary sequences located in the 3' -UTR region of the target genes, resulting in degradation of the mRNA or suppression of translation.¹⁸⁶ *MIR184*, in particular, encodes for miR-184, which is expressed in the central corneal epithelial cells and the lens epithelium.^{187–189} It is the most abundant miRNA in both the cornea and the lens and it is known to competitively inhibit the binding of miR-205 to the mRNA of the inositol polyphosphate phosphatase-like 1 gene (*INPPL1*, also known as *SHIP2*).^{189,190} This neutralizes the inhibitory activity of miR-205 on *INPPL-1* and subsequently downregulates the Akt pathway, which has been shown to markedly increase keratinocyte apoptosis and cell death.¹⁹⁰ Interestingly, this situation is unique to the corneal epithelium as it is the only known epithelium that exhibits overlapping expression of miR-184 and miR-205.^{189,190} Additionally, miR-184 has been shown to regulate differentiation of human-induced pluripotent stem cells into corneal epithelial-like cells.^{191,192}

Given its role in the cornea, it is not surprising that mutations in *MIR184* may lead to KC. To date, multiple studies have identified a heterozygous mutation in *MIR184* in a Northern Ireland family with KC and cataracts,¹⁸⁷ a family with EDICT (endothelial dystrophy, iris hypoplasia, congenital cataract, and stromal thinning) syndrome,¹⁹³ and an European Spanish family with various corneal abnormalities including severe KC.¹⁹⁴ However, the lack of mutations in KC patients from Iran,¹⁹¹ Turkey,¹⁹⁵ and Saudi Arabia¹⁹⁶ suggests a limited role of *MIR184* in KC pathogenesis.¹⁹⁶

Specific miRNAs have also been associated with T2DM cellular processes, including apoptosis, response to cytokines, and insulin secretion.¹⁹⁷ miR-184, in particular, has been identified as an important modulator of compensatory pancreatic β -cell expansion during insulin resistance.^{198–200} Generally, the expression of miR-184 is increased in islet cells in periods of fasting, demonstrating an active role in pancreatic β -cells as the glucose levels decrease.²⁰¹ Likewise, the miR-184 expression levels have been shown to decrease in the presence of increasing extracellular glucose.²⁰¹ Together, this highlights the potential role of miR-184 in glucose metabolism. Furthermore, its expression is strongly decreased in the pancreatic islet cells of insulin-resistant mouse models and human patients with T2DM.²⁰⁰ miR-184 expression and activity needs to be further studied in the DM cornea. Given its regulation by glucose levels in pancreatic islet cells, it is possible that miR-184 may be similarly downregulated by high glucose levels in the DM cornea, thus inhibiting cellular apoptosis and resulting in corneal thickening.

5. Inflammation and oxidative stress in the cornea

Although KC has traditionally been described as a noninflammatory degenerative condition, there is emerging evidence suggesting that inflammation within the epithelium and stroma

are involved in the pathogenesis of KC.³ Multiple studies have observed significant increases in proinflammatory molecules such as IL-6, IL-4, IL-5, IL-8, and IL-12^{169,202} in KC tears compared to controls. Additionally, KC keratocytes have been reported to express more IL-1 α receptors,²⁰³ which may trigger keratocyte apoptosis since IL-1 α is a proinflammatory cytokine.²⁰⁴

In parallel, several studies have found that oxidative stress is involved in the development and progression of KC.^{83,205–207} KC corneas have exhibited abnormalities such as increased levels of inducible nitric oxide synthase, nitrotyrosine, malondialdehyde, and glutathione S-transferase,²⁰⁸ as well as decreased activities of extracellular superoxide dismutase.²⁰⁵ This is supported by multiple observations of KC corneas and fibroblasts exhibiting increased levels of ROS and relatively greater mitochondrial DNA damage as compared to controls.^{207,209,210} Interestingly, the combination of oxidative stress and hyperglycemia, particularly in T2DM, accelerates AGE formation.⁸⁰ Thus, with increased AGE accumulation, this may create the potential for increased inflammation, enhanced production of ROS, and impairment of DNA repair mechanisms⁸⁰ in the DM cornea as well.

The increase in inflammatory markers and ROS within the KC cornea may be the result of environmental stimuli such as eye-rubbing and external oxidants such as UV light, which drives the pathological thinning of the stroma.²¹¹ DM itself is an inflammatory systemic disease, so we wanted to explore its effects on the KC-associated genes. In this section, we focused on *HGF*, *CAST*, *SOD1*, and *IL1A/IL1B* and their roles in DM and KC pathophysiology (Table 2).

5.1. HGF

Hepatocyte growth factor (HGF) is a pleiotropic growth factor that binds to its receptor, mesenchymal-epithelial transition factor (c-Met/ Met) and activates multiple downstream pathways, including MAPK, PI3K-Akt axis, and activators of transcription (JAK/STAT) pathways.²¹² It is primarily involved in cell proliferation and migration, particularly in corneal epithelial cells, as well as inflammatory-related signaling cascades.^{3,213,214} Injured corneas have exhibited increased *HGF* and *c-Met* mRNA expression during corneal wound healing.^{214–216}

The genetic association between *HGF* variants and KC susceptibility was identified with several *HGF* SNPs in the European and Australian cohort studies.^{50,217,218} Given that all the currently identified SNPs are located in a noncoding region upstream of *HGF*, it was suggested that they regulate gene expression by way of RNA splicing, transcription factor binding, and miRNA regulation.^{3,219} Additionally, there is recent evidence of increased HGF protein in the KC epithelium compared to control corneal epithelium.³ This suggests that poorly regulated and overexpressed HGF may have detrimental effects on the ECM due to inflammation in KC.

In diabetic corneas, both *ex vivo* and organ culture, HGF expression was noted to be increased with a corresponding decrease in HGF receptor c-Met expression.²²⁰ This suggests a disruption in the HGF/c-Met system, such that there is reduced cell migration and poor epithelial healing, which is characteristic of diabetic corneas.^{221–223} This hypothesis

is supported by the finding that overexpression of c-met in diabetic corneas resulted in restoration of nearly normal epithelial wound healing times.²²³ In other DM studies, HGF has been shown to play a role in the metabolic flux of glucose, manage β -cell homeostasis, and modulate the inflammatory response.²²⁴ Thus, it is possible that reduced receptor c-Met expression in DM corneas could serve a protective role against the inflammatory response mediated by HGF.

5.2. CAST

CAST encodes calpastatin, an inhibitor of calpains. *CAST* is a calcium-dependent cysteine protease that is involved in a variety of cellular processes, including proliferation, apoptosis, and cell migration.²²⁵ The calpain/calpastatin system is present in the corneal epithelium where it is suspected to play a role in epithelial cell turnover and wound healing.^{226,227} It has also been localized to corneal endothelial cells and fibroblasts.^{226,228} Genotyping of both Caucasian and Han Chinese patients with KC revealed a consistent association between variants near or within *CAST*, with KC susceptibility.^{226,229}

In DM, calpain activity has been shown to be increased in vascular endothelial cells in response to excess glucose.^{127,230–233} Calpain may also play a role in mitochondrial ROS generation, such that it contributes to diabetic vascular injury by way of vascular inflammation^{232,234} and glucose-induced apoptosis in endothelial cells.^{230,235} This is supported by the finding that genetic inhibition of calpain through over-expression of calpastatin reduces vascular ROS production.²³⁰ Increased glucose-induced calpain activity has also been shown to initiate vascular endothelial dysfunction by inactivating prostacyclin (PGI_2), as overexpression of endogenous calpastatin inhibited this effect.²³⁶ A similar mechanism may be observed in DM corneas, as calpain is activated by high-glucose levels. Analyzing the expression and activity levels of *CAST* in KC and DM corneas will give us further insight into this pathway.

5.3. SOD1

Superoxide dismutase 1 (*SOD1*) encodes a copper and zinc-dependent cytoplasmic enzyme that is directly involved in the antioxidative processes associated with ROS elimination and reduction of oxidative stress in the cornea.²⁰⁵ It has been shown to localize to the corneal epithelium, endothelium, and keratocytes.²⁰⁵ Given that there have been increased levels of oxidative stress markers in the KC cornea, several studies have suggested that mutations in *SOD1* might be involved in development of KC.^{48,83,237} A specific *SOD1* deletion was detected in two non-related American families with an autosomal dominant form of KC as well as in the Greek and Brazilian KC population.^{238–240} Mutational analyses revealed that this deletion excluded the *SOD1* protein active site, which suggests a loss of enzyme function.²³⁹ Although the specific *SOD1* deletion has had a low frequency in cohort studies, the fact that it has been identified in various populations suggests that it might serve as a potential genetic component in the development of KC. This is supported by the finding of suppressed levels of *SOD1* expression in KC corneal fibroblast cultures as compared to controls.²⁴¹ However, this is a controversial topic as other studies have refuted *SOD1*'s involvement as there was not enough evidence in mutational analyses.^{48,127,237,242–246}

Mutations in the *SOD1* gene has also long been associated with amyotrophic lateral sclerosis (ALS). It is generally accepted that mutations in *SOD1* results in conformational instability of the protein, resulting in the formation of SOD1 aggregates that exert a cytotoxic effect in motor neurons, which then results in the progressive degeneration of motor neurons observed in ALS.²⁴⁷ Interestingly, ALS has recently been shown to share several genetic pathways with DM.²⁴⁸ Additionally, several genetic variations of *SOD1* polymorphism have been associated with diabetes and diabetic complications.^{249–254} One study implicated a role for AGE/RAGE signaling in DM-mediated vascular calcification through activation of Nox-1 and decreased expression of SOD1, which increased oxidative stress.²⁵⁵ Recently, a separate study investigated ocular surface damage in diabetic mice and found an accumulation of ROS, increased expression of RAGE, and decreased *SOD1* expression in the cornea.²⁵⁶ This study also reported that topical treatment with pigment epithelium-derived factor (PEDF) was shown to improve corneal epithelial damage by decreasing RAGE and increasing SOD1 expression.²⁵⁶ Together, this suggests that SOD1 may play an important role in alleviating the oxidative stress seen in corneal pathology. SOD1's role in KC pathogenesis is currently under debate, but it is possible that increased AGE/RAGE activity in the DM cornea results in decreased SOD1 expression.

5.4. IL1A and IL1B

Interleukin (IL)-1 is a proinflammatory cytokine involved in various cellular activities, including cell proliferation, differentiation, and apoptosis.²⁵⁷ The IL-1 family includes two proinflammatory cytokines, IL-1 α and IL-1 β , and the IL-1 receptor antagonist (IL-1Ra), encoded by *IL1A*, *IL1B*, and *IL1RN*, respectively.²⁵⁷ IL-1 has been shown to upregulate keratocyte expression of collagenases, metalloproteinases, and other enzymes involved in collagen remodeling during corneal wound healing.^{258,259} Early studies detected increased keratocyte apoptosis in KC corneas and suggested that it might be triggered by increased basal IL-1 release.^{260,261} This is supported by the finding of increased IL-1 α binding sites in KC corneal fibroblasts compared to control corneas.²⁰³ However, genetic association analyses for polymorphisms in *IL1A* and *IL1B* in KC have remained controversial. Genetic associations with KC have been identified with variants in *IL1B* in the Han Chinese,²⁶² Korean,²⁶³ and Japanese KC population,²⁵⁷ but the involvement of *IL1A* was only observed in the Han Chinese KC population.²⁶² Furthermore, no genetic associations with variants in or near *IL1A* or *IL1B* were observed in the Turkish population.²⁶⁴ To date, it is still unclear how the mRNA expression levels of *IL1A* and *IL1B* relates to the expression of cytokines IL-1 α and IL-1 β in KC pathophysiology.

The IL-1 family of cytokines has also been implicated in DM and DM-related complications by way of inflammation.^{265–268} To better understand the role of IL-1 in the diabetic cornea and corneal wound healing, a recent study utilized a genome-wide cDNA array analysis in normal and DM mouse corneas.²⁶⁸ This study by Yan et al., 2016 reported upregulation of IL-1 β expression in the healing corneal epithelium of both normal and DM corneas, with no difference in IL-1 α expression.²⁶⁸ There was a corresponding increase in *IL1RN* expression in the normal cornea, but a decrease in the DM cornea, suggesting a disturbed balance of IL-1 β to IL-1Ra.²⁶⁸ This disruption in IL-1Ra signaling had multiple adverse effects in corneal wound healing, including suppression of proinflammatory cytokine/chemokine

expression and a decrease in the overall early inflammatory response to wounding in DM mouse corneas.²⁶⁸ Interestingly, increased production of IL-1 β has also been observed in macrophages in response to prolactin stimulation.²⁶⁹ Given that prolactin-induced protein has recently been suggested to be a novel biomarker for KC,^{270,271} this is an intriguing association between the balance of IL-1 β to IL-1Ra signaling and hormonal influences.

A separate cross-sectional analysis reported increased levels of IL-1Ra in patients with prevalent DM or metabolic syndrome.¹⁶² It was suggested that the increased IL-1Ra expression levels predicted the progression of metabolic syndrome to clinically incident diabetes, independently of CRP and other risk factors.¹⁶² This study also revealed genetic variants in *IL1A*, *IL1B*, and *IL1RN* that may have gender-specific associations with DM.¹⁶² Further studies will be required to better understand how the genetic variants in *IL1A* and *IL1B* influence expression of IL-1 α and IL-1 β and whether there is differential regulation of the IL-1 family in KC and DM.

6. Additional genes of interest

Multiple other genes have been associated with CCT and KC pathophysiology, including but not limited to *SPRY2* and *COL4A3/ COL4A4*^{48,49} (Table 2). Here, we discuss how these genes may potentially have overlapping or differing roles in KC and DM pathogenesis.

6.1. SPRY2

The Sprouty family consists of four members, SPRY1–4. All are direct targets and negative feedback regulators of fibroblast growth factor (FGF) signaling,^{272–274} playing important roles in the early development of multiple organs.^{273,275,276} SPRY2, in particular, has been shown to modulate the apoptotic actions induced by pro-inflammatory cytokine, TNF- α .²⁷⁷ Kuchara et al., 2011 revealed an important role for Spry1 and Spry2 in the regulation of lens vesicle separation and corneal epithelial proliferation in mouse models.²⁷⁸ This study generated *Spry1;Spry2* double-null mutants and observed increased corneal epithelial proliferation and an inhibition in terminal differentiation.²⁷⁸ A later study revealed that eyelid closure was impaired due to increased proliferation of conjunctival epithelial cells in Spry conditional knock-out mutants.²⁷⁹ This suggests that Spry-1 and Spry-2 normally suppress ectopic growth in the corneal epithelial tissue. A recent GWAS identified *SPRY2* as a novel candidate gene significantly associated with CCT inter-individual variation.⁴⁹ Although no studies have analyzed SPRY2 in KC pathogenesis, it is possible that it may contribute to alterations in the corneal epithelium.

Recently, a variant near *SPRY2* was found to be associated with increased susceptibility to T2DM in both the Han Chinese and Japanese population.^{280,281} *SPRY2* KO in human hepatocyte cells resulted in increased glucose intake, suggesting a possible role for SPRY2 in glucose metabolism in hepatocytes.²⁸² This same study also reported the upregulated genes in *SPRY2* KO cells to be involved with DNA replication and cell cycle regulation, which is consistent with its established role in inhibition of cellular proliferation.²⁸² Taken together, deletions in *SPRY2* may have pathologic effects in both the cornea and metabolic homeostasis.

6.2. COL4A3/COL4A4

COL4A3 and *COL4A4* both encode for collagen type IV, the major structural component in epithelial and endothelial basement membranes in the human cornea.^{283,284} Collagen type IV mutations have been implicated in a variety of clinical manifestations, including Alport syndrome and PPCD.^{140,283,285} Both genes have been reported to be differentially expressed in KC corneas, suggesting a role for collagen type IV in KC pathogenesis.^{153,286} However, in genetic analyses of *COL4A3* and *COL4A4*, no pathogenic variants were identified in KC patients, although common polymorphisms are present in the affected and healthy populations.^{48,86,283,287,288} Thus, the role of collagen type IV mutations in KC pathogenesis is unclear.

Collagen type IV is also a major structural component of the glomerular basement membrane (GBM), and alterations in the collagen composition have been implicated in the pathogenesis of nephropathy in DM.²⁸⁹ GWAS meta-analysis of T1DM revealed a SNP rs55703767 that resulted in thinner GBM in patients with DM but was protective against renal complications.²⁹⁰ Interestingly, Onochie et al., 2020 reported that hypoxia induced a reduction in laminin and collagen type IV in the cornea, which resulted in a delay in wound healing and increased corneal stiffness.²⁹¹ This was in parallel to the finding of impaired wound healing and a decrease in laminin along the basal lamina in the diabetic cornea.²⁸⁴ Given that diabetes can cause a transition to a hypoxic state, this suggests a potential role for collagen type IV in the induction of increased corneal stiffness that has been reported in DM.²⁹¹ Further studies will be needed to see if collagen type IV mutations have a potential effect on the DM cornea and to better understand how hypoxia affects collagen type IV.

7. Discussion

Multiple retrospective epidemiological studies have suggested that patients with DM have reduced risk in the development and/or severity of keratoconus (Table 1).^{13,14,17,18} Seiler et al., 2000 was among the first to report this protective role of DM in a retrospective case-control study of the German population.¹³ This finding was later confirmed by Naderan et al., 2014 in the Iranian population,¹⁷ and Kuo et al., 2006 in the United States population.¹⁴ One limitation of the above studies is that the data was extracted from the hospital/clinic population. Woodward et al., 2016 addressed this by conducting a retrospective longitudinal population-based cohort study in the United States.¹⁸ With a larger sample size, Woodward et al., 2016 found that there were 20% lower odds of KC development with uncomplicated DM and 52% lower odds of KC development with DM-associated complications.¹⁸

A common working hypothesis in support of this observation is that chronic hyperglycemia promotes glycosylation of corneal fibers and induces endogenous collagen crosslinking within the corneal stroma, thus preventing the biomechanical weakening of the cornea.^{13,34} Although the cornea is an avascular structure, previous reports have indicated that corneas in diabetic patients are still exposed to increased glucose concentration,^{292–294} which supports this hypothesis. Another working hypothesis is that DM disrupts corneal endothelial cell function, resulting in stromal edema and increased CCT^{35,37,295–297} (Fig. 1).

This remains a debated topic as other studies have either 1) suggested a positive association between KC and DM or 2) did not identify a significant correlation (Table 1).^{14,19–22} For example, Kosker et al., 2014 conducted a retrospective case-control and cross-sectional study in the United States population and reported a higher prevalence of T2DM in the KC population as well as greater severity of KC in DM patients.²⁰ However, this was clinic-based, and the prevalence of DM in clinic populations as compared to the general population may account for differences in these findings. Subsequently, Moon et al., 2020 conducted a retrospective cohort population-based study in the Korean population and they also reported a higher prevalence of T2DM in the KC population with a positive association of KC and DM.²¹ In contrast, Bak-Nielsen et al., 2019¹⁹ and Lee et al., 2020²⁹⁸ conducted a retrospective cohort study in the Danish and Korean population, respectively, and found no significant differences in DM prevalence in KC patients. In efforts to consolidate the findings, Hashemi et al., 2020²⁹⁹ conducted a meta-analysis and reported that although the odds of developing KC were 23% lower, this relationship was not significant. A limitation of this meta-analysis is that all studies included were either cross-sectional or case-control studies, which can be more prone to information and selection bias compared to cohort studies.²⁹⁹ Thus, the variations in study designs likely contribute to differences in findings.

The multiple effects of DM on the cornea are complex and have been reviewed elsewhere.^{16,26,300,301} These DM effects include, but are not limited to, keratopathy, neuropathy, inflammation, alterations in collagen fibrils, endothelial cell loss, and increased glucose in the aqueous humor.^{16,292} Patients with DM are often predisposed to ocular surface complications such as dry eye, recurrent corneal erosions, and bacterial infection.^{26,302–304} However, the mechanism of correlation between DM and KC pathogenesis remains unclear. In efforts to better understand KC pathophysiology, multiple candidate and genome-wide association studies have identified the genetic and metabolic components involved in KC.^{48,49,100,305} Additionally, a recent review outlined important biological and chemical pathways related to collagen crosslinking in DM and KC.²⁶

In terms of corneal biomechanics, KC is characterized by localized stromal corneal thinning and reduced CCT,¹ while DM generally causes the cornea to become stiffer with increased CCT and/or CH.^{13,34,35,37} This is likely reflected by changes in the collagen composition of the cornea, as outlined by McKay et al., 2019.²⁶ Two genes, *LOX* and *COL5A1*, may play important roles in corneal collagen crosslinking. Current evidence suggests that overall LOX activity (including LOX and LOXL proteins) is decreased in KC, leading to impairment of lysyl oxidase-mediated crosslinking and weakening of the cornea.^{45,54} In contrast, hyperglycemic conditions have been shown to upregulate LOX expression and activity in retinal cells.^{58,60} If a similar effect may be seen in corneal cells under hyperglycemic conditions, this could explain the reduced risk of KC development in DM patients. Given that *COL5A1* reached genome-wide significance in KC patients, and that patients with *COL5A1* haploinsufficiency exhibited corneal thinning, we discussed whether *COL5A1* shared similar genetic significance in DM corneal pathology. To our knowledge, no studies have analyzed DM's direct effects on *COL5A1* in the cornea. A recent study did find differential collagen composition with elevated levels of collagen types I and type III, but not collagen type V, in the human corneal stroma of DM patients. This finding suggests that hyperglycemia may induce collagen modulation in an isoform-dependent

manner. Further studies are needed to better understand the effects of hyperglycemia and increased AGE-mediated crosslinking on the various collagen isoforms in DM corneas, and to determine whether sequence variants in or near *COL5A1* are associated with KC and DM cornea pathology.

Alterations in corneal biomechanics is also characterized by disruption in the ECM composition of the cornea. Thus, we explored several genes that play a role in ECM remodeling and were identified in KC and CCT-associated GWAS. This includes several transcription factors including *FOXO1*, *SMAD3*, *TGFBI*, and *ZEB1*. It became readily apparent that the investigation of these genes is lacking in the DM cornea, but many exhibited an association with AGE-mediated signaling and differential expression under hyperglycemic conditions in other tissues. This suggests that a similar effect could be seen in the DM cornea, but further research studies will be needed to confirm this. TGF β signaling would be worth exploring further in the KC and DM cornea, as it has been associated with alterations in SMAD3, TGFBIp and FOXO1 signaling. For example, increased TGF β signaling and SMAD3 activity has been suggested to increase ECM deposition in mesangial cells, leading to the development of DN. This, in combination with an imbalance in MMP-9/TIMP-1 activity, may contribute to different degrees of ECM remodeling in the cornea of KC and DM patients. Additionally, *MIR184* has a very unique role in the remodeling of the corneal epithelium. Given its downregulation by high glucose levels in pancreatic islet cells, *MIR184* may potentially link elevated glucose levels and alterations in corneal epithelial cell apoptosis in the DM cornea.

Interestingly, there was genetic overlap in several inflammatory proteins and regulators of oxidative stress in both KC and DM. Although KC was previously described as a noninflammatory condition, it has been suggested that external environmental factors such as excessive eye rubbing may induce an increase in inflammatory markers, contributing to KC pathogenesis. Likewise, DM has been associated with low-grade inflammation that is thought to contribute to insulin resistance observed in T2DM.³⁰⁶ In this review, we closely examined the role of *HGF*, *CAST*, *SOD1*, and *IL1A/IL1B*. While *HGF*'s role remains unclear, the imbalance in HGF and HGF receptor c-Met expression in DM corneas is intriguing, which could lend towards a protective role against inflammatory degradation in the ECM of DM. We found that *SOD1* likely plays a similar role in reducing oxidative stress, as decreased *SOD1* expression has been suggested in both KC and DM. Further studies into the calpain/calpastatin system, as well as the ratio of IL-1 α /IL-1 β to IL-1Ra, will be needed before an association can be made between DM and KC. It is possible that imbalances in both systems may contribute to the differing clinical pathology observed in the cornea.

Last but not least, multiple other genes have been associated with KC pathophysiology, but their roles in DM are unclear. We highlighted a few remaining KC candidate genes, including *SRPY2* and *COL4A3/COL4A4*. However, much more extensive studies are required before correlations can be made with DM. We suggest exclusively studying the DM cornea with a focus on KC-associated genes and analyzing the expression patterns of associated proteins.

From a clinical perspective, the age of onset for KC often ranges from the teenage years to the 30s and 40s while the age of onset for type 2 DM ranges from teenage years to the 70s.^{1,271,307–309} Type 2 DM is becoming increasingly prevalent in children and adolescents worldwide, including the US. The average age of diagnosis for children and adolescents in the US is 14 years.³⁰⁷ The incomplete overlap in age-onset between KC and DM may complicate efforts in interpreting the potential protective effect of DM on KC. This raises an important question to all the reported studies: what is the distribution of DM age-onset for those with KC or without KC? It will be more beneficial to only include DM patients with age-onset less than 30–40 years.

8. Conclusion

Despite the conflicting literature evidence between KC and DM, our comprehensive discussion explained whether and how DM is associated with KC and how DM may function as a protective mechanism (Fig. 1). At this time, there is more evidence to support the protective role of DM in KC patients. If true, we hope to identify potential localized therapeutic targets in KC management that act by strengthening the KC cornea through similar mechanisms that may alter the DM cornea. One such example would be targeting *LOX* in the KC cornea and increasing its expression such that LOX-mediated collagen-crosslinking is increased, thus resulting in corneal thickening. Additionally, by targeting inflammatory cascades such as the calpain/calpastatin system and the IL-1 α /IL-1 β to IL-1Ra ratio, we can then potentially halt the inflammatory-mediated corneal thinning seen in KC. To conclude, by analyzing potential genetic associations in KC and DM, this review illustrates the areas where the current literature is lacking, with the hope of providing direction for future studies in elucidating the pathophysiology of KC and DM in the cornea. Future research would have tremendous benefit in identifying potential therapeutic targets in clinical management of KC.

9. Literature search

A comprehensive literature search completed by the end of September 2020 was performed on Pubmed. All selected articles were reviewed thoroughly by the authors to consolidate candidate genes that have been identified in genetic analyses and genome wide studies of keratoconus and central corneal thickness variations. We then explored how those respective genes may be similarly or differentially regulated under hyperglycemic conditions and the role they play in the systemic complications associated with diabetes.

Acknowledgement

We acknowledge the support of The Graduate School of Augusta University and the Medical College of Georgia.

Funding

This work was supported by the National Institutes of Health [grant numbers R01EY023242, R21EY028671, and P30EY031631]; and the startup fund from the Medical College of Georgia at Augusta University, Augusta, GA, USA.

Abbreviations

ALS	amyotrophic lateral sclerosis
AGE	advanced glycation end product
CAST	calpastatin
CCT	central corneal thickness
CH	corneal hysteresis
CRF	corneal resistance factor
DM	diabetes mellitus
DN	diabetic nephropathy
DR	diabetic retinopathy
ECM	extracellular matrix
EDS	Ehler-Danlos syndrome
EMT	epithelial to mesenchymal transition
FECD	Fuch's endothelial corneal dystrophy
FOXO1	forkhead box protein O1
GBM	glomerular basement membrane
GWAS	genome-wide association studies
HGF	hepatocyte growth factor
IHC	immunohistochemistry
KC	keratoconus
lncRNA	long noncoding RNA
LOX	lysyl oxidase
miRNA	microRNA
MMP	matrix metalloproteinases
PPCD	posterior polymorphous corneal dystrophy
RAGE	receptor for advanced glycation end products
SOD1	superoxide dismutase 1
TIMP	tissue inhibitors of metalloproteinases
TGFBI	transforming growth factor beta-induced

TGFBIp	transforming growth factor beta-induced protein
VSX1	visual system homeobox 1
ZEB1	zinc finger E box-binding homeobox 1

References

1. Rabinowitz YS. Keratoconus. *Survey of Ophthalmology*. 1998;42(4):297–319. [PubMed: 9493273]
2. Sykakis E, et al. An in depth analysis of histopathological characteristics found in keratoconus. *Pathology*. 2012;44(3):234–239. [PubMed: 22406479]
3. You J, et al. Expression of HGF and c-met proteins in human keratoconus corneas. *J Ophthalmol*. 2015;2015:852986.
4. Gordon-Shaag A, et al. The genetic and environmental factors for keratoconus. *BioMed Res Int*. 2015;2015:795738.
5. Lucas SEM, Burdon KP. Genetic and environmental risk factors for keratoconus. *Annu Rev Vis Sci*. 2020.
6. Sugar J, Macsai MS. What causes keratoconus? *Cornea*. 2012;31(6).
7. Alio JL, et al. Corneal morphologic characteristics in patients with down syndrome. *JAMA Ophthalmol*. 2018;136(9):971–978. [PubMed: 29931124]
8. Beckh U, Schoenherr U, Naumann GO. [Autosomal dominant keratoconus as the chief ocular symptom in Lobstein osteogenesis imperfecta tarda]. *Klin Monbl Augenheilkd*. 1995;206(4):268–272. [PubMed: 7791289]
9. Khaled ML, et al. Molecular and histopathological changes associated with keratoconus. *BioMed Res Int*. 2017:7803029, 2017.
10. Robertson I. Keratoconus and the Ehlers-Danlos syndrome: a new aspect of keratoconus. *Med J Aust*. 1975;1(18):571–573. [PubMed: 1143149]
11. Nemet AY, et al. The association of keratoconus with immune disorders. *Cornea*. 2010;29(11):1261–1264. [PubMed: 20802320]
12. Billcliff PG, Lowe M. Inositol lipid phosphatases in membrane trafficking and human disease. *Biochem J*. 2014;461(2):159–175. [PubMed: 24966051]
13. Seiler T, et al. Manifest diabetes and keratoconus: a retrospective case-control study. *Graefes Arch Clin Exp Ophthalmol*. 2000;238(10):822–825. [PubMed: 11127568]
14. Kuo IC, et al. Is there an association between diabetes and keratoconus? *Ophthalmology*. 2006;113(2):184–190. [PubMed: 16368147]
15. Naderan M, et al. Characteristics and associations of keratoconus patients. *Cont Lens Anterior Eye*. 2015;38(3):199–205. [PubMed: 25707930]
16. Ljubimov AV. Diabetic complications in the cornea. *Vis Res*. 2017;139:138–152. [PubMed: 28404521]
17. Naderan M, et al. Association between diabetes and keratoconus: a case-control study. *Cornea*. 2014;33(12):1271–1273. [PubMed: 25343697]
18. Woodward MA, Blachley TS, Stein JD. The association between sociodemographic factors, common systemic diseases, and keratoconus: an analysis of a nationwide health care claims database. *Ophthalmology*. 2016;123(3), 457–65.e2. [PubMed: 26707415]
19. Bak-Nielsen S, et al. A nationwide population-based study of social demographic factors, associated diseases and mortality of keratoconus patients in Denmark from 1977 to 2015. *Acta Ophthalmol*. 2019;97(5):497–504. [PubMed: 30426693]
20. Kosker M, et al. Another look at the association between diabetes and keratoconus. *Cornea*. 2014;33(8):774–779. [PubMed: 24915014]
21. Moon JY, et al. Incidence of keratoconus and its association with systemic comorbid conditions: a nationwide cohort study from South Korea. *J Ophthalmol*. 2020;2020: 3493614.
22. Claessens JLJ, et al. Nationwide epidemiological approach to identify associations between keratoconus and immune-mediated diseases. *Br J Ophthalmol*. 2021. *bjophthalmol-2021–318804*.

23. Galvis V, et al. Patient selection for corneal collagen cross-linking: an updated review. *Clin Ophthalmol.* 2017;11:657–668. [PubMed: 28435217]
24. Kling S, Hafezi F. Corneal biomechanics – a review. *Ophthalmic Physiol Opt.* 2017; 37(3):240–252. [PubMed: 28125860]
25. Ma J, et al. Biomechanics and structure of the cornea: implications and association with corneal disorders. *Surv Ophthalmol.* 2018;63(6):851–861. [PubMed: 29857022]
26. McKay TB, Priyadarsini S, Karamichos D. Mechanisms of collagen crosslinking in diabetes and keratoconus. *Cells.* 2019;8(10).
27. Priyadarsini S, et al. Complete metabolome and lipidome analysis reveals novel biomarkers in the human diabetic corneal stroma. *Exp Eye Res.* 2016;153:90–100. [PubMed: 27742548]
28. Weston BC, et al. Corneal hydration control in diabetes mellitus. *Invest Ophthalmol Vis Sci.* 1995;36(3):586–595. [PubMed: 7890490]
29. Kenney M, et al. Abnormalities of the Extracellular Matrix in Keratoconus Corneas. 16. 1997:345–351, 3.
30. Ertan A, Muftuoglu O. Keratoconus Clinical Findings According to Different Age and Gender Groups. 27. 2008:1109–1113, 10.
31. Li X, Yang H, Rabinowitz YS. Longitudinal study of keratoconus progression. *Exp Eye Res.* 2007;85(4):502–507. [PubMed: 17681291]
32. Blackburn BJ, et al. A Review of Structural and Biomechanical Changes in the Cornea in Aging, Disease, and Photochemical Crosslinking. 7. 2019, 66.
33. Sady C, Khosrof S, Nagaraj R. Advanced maillard reaction and crosslinking of corneal collagen in diabetes. *Biochem Biophys Res Commun.* 1995;214(3):793–797. [PubMed: 7575546]
34. Goldich Y, et al. Effect of Diabetes Mellitus on Biomechanical Parameters of the Cornea. 35. 2009:715–719, 4.
35. Busted N, Olsen T, Schmitz O. Clinical observations on the corneal thickness and the corneal endothelium in diabetes mellitus. *Br J Ophthalmol.* 1981;65(10):687. [PubMed: 7317320]
36. Keoleian GM, et al. Structural and Functional Studies of the Corneal Endothelium in Diabetes Mellitus. 113. 1992:64–70, 1.
37. Lee JS, et al. Differences in corneal thickness and corneal endothelium related to duration in diabetes. *Eye.* 2006;20(3):315–318. [PubMed: 15832184]
38. Sanchez-Thorin JC. The cornea in diabetes mellitus. *Int Ophthalmol Clin.* 1998; 38(2):19–36. [PubMed: 9604736]
39. Su DH, et al. Diabetes, hyperglycemia, and central corneal thickness: the Singapore Malay Eye Study. *Ophthalmology.* 2008;115(6):964–968.e1. [PubMed: 17964654]
40. Hager A, Wegscheider K, Wiegand W. Changes of extracellular matrix of the cornea in diabetes mellitus. *Graefes Arch Clin Exp Ophthalmol.* 2009;247(10):1369–1374. [PubMed: 19437029]
41. Scheler A, Spoerl E, Boehm AG. Effect of diabetes mellitus on corneal biomechanics and measurement of intraocular pressure. *Acta Ophthalmol.* 2012;90(6):e447–e451. [PubMed: 22691299]
42. Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. *J Cell Biochem.* 2003;88(4):660–672. [PubMed: 12577300]
43. Lucero HA, Kagan HM. Lysyl oxidase: an oxidative enzyme and effector of cell function. *Cell Mol Life Sci.* 2006;63(19–20):2304–2316. [PubMed: 16909208]
44. Coral K, et al. Lysyl Oxidase Activity in the Ocular Tissues and the Role of LOX in Proliferative Diabetic Retinopathy and Rhegmatogenous Retinal Detachment. 49. 2008: 4746–11.
45. Dudakova L, et al. Changes in lysyl oxidase (LOX) distribution and its decreased activity in keratoconus corneas. *Exp Eye Res.* 2012;104:74–81. [PubMed: 23041260]
46. Sethi A, et al. Transforming growth factor- β induces extracellular matrix protein cross-linking lysyl oxidase (LOX) genes in human trabecular meshwork cells. *Investigative Ophthalmology & Visual Science.* 2011;52(8):5240–5250. [PubMed: 21546528]
47. Bykhovskaya Y, et al. Variation in the lysyl oxidase (LOX) gene is associated with keratoconus in family-based and case-control studies. *Invest Ophthalmol Vis Sci.* 2012;53(7):4152–4157. [PubMed: 22661479]

48. Bykhovskaya Y, Margines B, Rabinowitz YS. Genetics in Keratoconus: where are we? *Eye Vis (Lond)*. 2016;3:16. [PubMed: 27350955]
49. Choquet H, et al. A multiethnic genome-wide analysis of 44,039 individuals identifies 41 new loci associated with central corneal thickness. *Communications Biology*. 2020;3(1):301. [PubMed: 32528159]
50. Dudakova L, et al. Validation of rs2956540:G>C and rs3735520:G>A association with keratoconus in a population of European descent. *Eur J Hum Genet*. 2015; 23(11):1581–1583. [PubMed: 25735481]
51. Hao XD, et al. Evaluating the association between keratoconus and reported genetic loci in a han Chinese population. *Ophthalmic Genet*. 2015;36(2):132–136. [PubMed: 25675348]
52. Hasanian-Langroudi F, et al. Association of lysyl oxidase (LOX) polymorphisms with the risk of keratoconus in an Iranian population. *Ophthalmic Genet*. 2015;36(4): 309–314. [PubMed: 24502826]
53. Zhang J, et al. Association of common variants in LOX with keratoconus: a meta- analysis. *PLoS One*. 2015;10(12), e0145815.
54. Shetty R, et al. Bilaterally asymmetric corneal ectasia following SMILE with asymmetrically reduced stromal molecular markers. *J Refract Surg*. 2019;35(1): 6–14. [PubMed: 30633782]
55. Schlotzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma—new insights from LOXL1 gene associations. *Exp Eye Res*. 2009;88(4): 776–785. [PubMed: 18809397]
56. Thorleifsson G, et al. Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science*. 2007;317(5843):1397–1400. [PubMed: 17690259]
57. Dudakova L, et al. The presence of lysyl oxidase-like enzymes in human control and keratoconic corneas. *Histol Histopathol*. 2016;31(1):63–71. [PubMed: 26218558]
58. Chronopoulos A, et al. High glucose increases lysyl oxidase expression and activity in retinal endothelial cells: mechanism for compromised extracellular matrix barrier function. *Diabetes*. 2010;59(12):3159–3166. [PubMed: 20823103]
59. Buckingham B, Reiser KM. Relationship between the content of lysyl oxidase- dependent cross-links in skin collagen, nonenzymatic glycosylation, and long-term complications in type I diabetes mellitus. *J Clin Invest*. 1990;86(4):1046–1054. [PubMed: 1976653]
60. Coral K, et al. High glucose induced differential expression of lysyl oxidase and its isoform in ARPE-19 cells. *Curr Eye Res*. 2013;38(1):194–203. [PubMed: 22966818]
61. Dimasi DP, et al. Novel quantitative trait loci for central corneal thickness identified by candidate gene analysis of osteogenesis imperfecta genes. *Hum Genet*. 2010; 127(1):33–44. [PubMed: 19714363]
62. Vithana EN, et al. Collagen-related genes influence the glaucoma risk factor, central corneal thickness. *Hum Mol Genet*. 2011;20(4):649–658. [PubMed: 21098505]
63. Vitart V, et al. New loci associated with central cornea thickness include COL5A1, AKAP13 and AVGR8. *Hum Mol Genet*. 2010;19(21):4304–4311. [PubMed: 20719862]
64. Hoehn R, et al. Population-based meta-analysis in Caucasians confirms association with COL5A1 and ZNF469 but not COL8A2 with central corneal thickness. *Hum Genet*. 2012;131(11):1783–1793. [PubMed: 22814818]
65. Li X, et al. Genetic association of COL5A1 variants in keratoconus patients suggests a complex connection between corneal thinning and keratoconus. *Invest Ophthalmol Vis Sci*. 2013;54(4):2696–2704. [PubMed: 23513063]
66. Lu Y, et al. Genome-wide association analyses identify multiple loci associated with central corneal thickness and keratoconus. *Nat Genet*. 2013;45(2):155–163. [PubMed: 23291589]
67. Birk DE. Type V collagen: heterotypic type I/V collagen interactions in the regulation of fibril assembly. *Micron*. 2001;32(3):223–237. [PubMed: 11006503]
68. Birk DE, et al. Collagen type I and type V are present in the same fibril in the avian corneal stroma. *J Cell Biol*. 1988;106(3):999–1008. [PubMed: 3346334]
69. Sun M, et al. Collagen V is a dominant regulator of collagen fibrillogenesis: dysfunctional regulation of structure and function in a corneal-stroma-specific Col5a1-null mouse model. *J Cell Sci*. 2011;124(Pt 23):4096–4105. [PubMed: 22159420]

70. Birk D, Bruckner P. The Extracellular Matrix: An Overview, *Biology of Extracellular Matrix*. 2011.
71. Birk DE, et al. Collagen fibrillogenesis in vitro: interaction of types I and V collagen regulates fibril diameter. *J Cell Sci*. 1990;95(Pt 4):649–657. [PubMed: 2384532]
72. Segev F, et al. Structural abnormalities of the cornea and lid resulting from collagen V mutations. *Investigative Ophthalmology & Visual Science*. 2006;47(2):565–573. [PubMed: 16431952]
73. Schwarze U, et al. Null alleles of the COL5A1 gene of type V collagen are a cause of the classical forms of Ehlers-Danlos syndrome (types I and II). *Am J Hum Genet*. 2000;66(6):1757–1765. [PubMed: 10796876]
74. Wenstrup RJ, et al. COL5A1 haploinsufficiency is a common molecular mechanism underlying the classical form of EDS. *Am J Hum Genet*. 2000;66(6):1766–1776. [PubMed: 1077716]
75. Rohlfing CL, et al. Defining the relationship between plasma glucose and HbA1c. *Diabetes Care*. 2002;25(2):275. [PubMed: 11815495]
76. Andreassen TT, Seyer-Hansen K, Bailey AJ. Thermal stability, mechanical properties and reducible cross-links of rat tail tendon in experimental diabetes. *Biochim Biophys Acta Gen Subj*. 1981;677(2):313–317.
77. Li Y, et al. Advanced glycation end-products diminish tendon collagen fiber sliding. *Matrix Biol*. 2013;32(3–4):169–177. [PubMed: 23348249]
78. Spoerl E, Wollensak G, Seiler T. Increased resistance of crosslinked cornea against enzymatic digestion. *Curr Eye Res*. 2004;29(1):35–40. [PubMed: 15370365]
79. Neeper M, et al. Cloning and Expression of a Cell Surface Receptor for Advanced Glycosylation End Products of Proteins. 267. 1992:14998–15004, 21.
80. Reynaert NL, et al. Advanced glycation end products and their receptor in age- related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease. *Int J Biochem Cell Biol*. 2016;81: 403–418. [PubMed: 27373680]
81. Ng KKK, et al. Possible modifying effect of hemoglobin A1c on genetic susceptibility to severe diabetic retinopathy in patients with type 2 diabetes. *Invest Ophthalmol Vis Sci*. 2020;61(10):7.
82. Smith VA, et al. Keratoconus: matrix metalloproteinase-2 activation and TIMP modulation. *Biochim Biophys Acta (BBA) Mol Basis Dis*. 2006;1762(4):431–439.
83. Kenney MC, et al. Increased levels of catalase and cathepsin V/L2 but decreased TIMP-1 in keratoconus corneas: evidence that oxidative stress plays a role in this disorder. *Investigative Ophthalmology & Visual Science*. 2005;46(3):823–832. [PubMed: 15728537]
84. Xing YQ, et al. The regulation of FOXO1 and its role in disease progression. *Life Sci*. 2018;193:124–131. [PubMed: 29158051]
85. Gao X, et al. A genome-wide association study of central corneal thickness in Latinos. *Invest Ophthalmol Vis Sci*. 2013;54(4):2435–2443. [PubMed: 23493294]
86. Abu-Amro KK, et al. Case-control association between CCT-associated variants and keratoconus in a Saudi Arabian population. *J Negat Results Biomed*. 2015;14:10. [PubMed: 26040312]
87. Yang J, et al. Insulin promotes proliferation and fibrosing responses in activated pancreatic stellate cells. *Am J Physiol Gastrointest Liver Physiol*. 2016;311(4): G675–G687. [PubMed: 27609771]
88. Kitamura T. The role of FOXO1 in β -cell failure and type 2 diabetes mellitus. *Nat Rev Endocrinol*. 2013;9(10):615–623. [PubMed: 23959366]
89. Wilhelm K, et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium. *Nature*. 2016;529(7585):216–220. [PubMed: 26735015]
90. Zhang H, et al. FoxO1 inhibits autophagosome-lysosome fusion leading to endothelial autophagic-apoptosis in diabetes. *Cardiovasc Res*. 2019;115(14): 2008–2020. [PubMed: 30689742]
91. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. *Cell*. 2003;113(6):685–700. [PubMed: 12809600]
92. Nakao A, et al. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. *Nature*. 1997;389(6651):631–635. [PubMed: 9335507]
93. Gomes LR, et al. TGF- β 1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. *BMC Canc*. 2012;12:26.

94. Schiller M, Javelaud D, Mauviel A. TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. *J Dermatol Sci.* 2004;35(2):83–92. [PubMed: 15265520]
95. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. *J Pathol.* 2003;200(4):448–464. [PubMed: 12845612]
96. Engler C, et al. Transforming growth factor- β signaling pathway activation in Keratoconus. *Am J Ophthalmol.* 2011;151(5):752–759.e2. [PubMed: 21310385]
97. Maier P, et al. Active transforming growth factor-beta2 is increased in the aqueous humor of keratoconus patients. *Mol Vis.* 2007;13:1198–1202. [PubMed: 17679942]
98. Priyadarasini S, et al. Keratoconus in vitro and the key players of the TGF- β pathway. *Mol Vis.* 2015;21:577–588. [PubMed: 26015770]
99. Tai TY, et al. Keratoconus associated with corneal stromal amyloid deposition containing TGFBIp. *Cornea.* 2009;28(5):589–593. [PubMed: 19421032]
100. Hosoda Y, et al. Keratoconus-susceptibility gene identification by corneal thickness genome-wide association study and artificial intelligence IBM Watson. *Commun Biol.* 2020;3(1):410. [PubMed: 32737415]
101. Yadav H, et al. TGF- β 1/Smad3 pathway targets PP2A-AMPK-FoxO1 signaling to regulate hepatic gluconeogenesis. *J Biol Chem.* 2017;292(8):3420–3432. [PubMed: 28069811]
102. Abe H, et al. Scleraxis modulates bone morphogenetic protein 4 (BMP4)-Smad1 protein-smooth muscle α -actin (SMA) signal transduction in diabetic nephropathy. *J Biol Chem.* 2012;287(24):20430–20442. [PubMed: 22474292]
103. Flyvbjerg A, et al. Long-term renal effects of a neutralizing RAGE antibody in obese type 2 diabetic mice. *Diabetes.* 2004;53(1):166–172. [PubMed: 14693711]
104. Belghith M, et al. TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. *Nat Med.* 2003;9(9):1202–1208. [PubMed: 12937416]
105. Huang C, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. *Diabetes.* 2002;51(12):3577–3581. [PubMed: 12453917]
106. Ono H, et al. Novel interplay between Smad1 and Smad3 phosphorylation via AGE regulates the progression of diabetic nephropathy. *Sci Rep.* 2018;8(1):10548. [PubMed: 30002389]
107. Kannabiran C. Genetics of corneal endothelial dystrophies. *J Genet.* 2009;88(4): 487–494. [PubMed: 20090209]
108. Han KE, et al. Pathogenesis and treatments of TGFBI corneal dystrophies. *Prog Retin Eye Res.* 2016;50:67–88. [PubMed: 26612778]
109. El-Shabrawi Y, et al. mRNA Levels of Alpha1 (VI) Collagen, Alpha1 (XII) Collagen, and Beta Ig in Rabbit Cornea during Normal Development and Healing. 39. 1998:36–44, 1.
110. Escribano J, et al. cDNA from Human Ocular Ciliary Epithelium Homologous to β ig-h3 Is Preferentially Expressed as an Extracellular Protein in the Corneal Epithelium. 160. 1994:511–521, 3.
111. Hirano K, et al. Beta ig-h3 is synthesized by corneal epithelium and perhaps endothelium in Fuchs' dystrophic corneas. *Curr Eye Res.* 1996;15(9):965–972. [PubMed: 8921218]
112. Leung EW, et al. Extracellular Matrix Components in Retrocorneal Fibrous Membrane in Comparison to Corneal Endothelium and Descemet's Membrane. 6. 2000:15–23.
113. Reinboth B, et al. Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. *J Biol Chem.* 2006;281(12):7816–7824. [PubMed: 16434404]
114. Hanssen E, Reinboth B, Gibson MA. Covalent and non-covalent interactions of betaig-h3 with collagen VI. Beta ig-h3 is covalently attached to the amino-terminal region of collagen VI in tissue microfibrils. *J Biol Chem.* 2003;278(27): 24334–24341. [PubMed: 12719415]
115. Kim JE, et al. Molecular properties of wild-type and mutant betaIG-H3 proteins. *Invest Ophthalmol Vis Sci.* 2002;43(3):656–661. [PubMed: 11867580]

116. Poulsen ET, et al. Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies. *FEBS J.* 2018;285(1):101–114. [PubMed: 29117645]
117. Runager K, et al. The insoluble TGFBIp fraction of the cornea is covalently linked via a disulfide bond to type XII collagen. *Biochemistry.* 2013;52(16):2821–2827. [PubMed: 23556985]
118. Bae JS, et al. Betaig-h3 supports keratinocyte adhesion, migration, and proliferation through alpha3beta1 integrin. *Biochem Biophys Res Commun.* 2002;294(5):940–948. [PubMed: 12074567]
119. Kim HJ, Kim IS. Transforming growth factor-beta-induced gene product, as a novel ligand of integrin alphaMbeta2, promotes monocytes adhesion, migration and chemotaxis. *Int J Biochem Cell Biol.* 2008;40(5):991–1004. [PubMed: 18083624]
120. Kim JE, et al. Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein betaig-h3 that interact with the alphavbeta5 integrin. *J Biol Chem.* 2002;277(48):46159–46165. [PubMed: 12270930]
121. Kim JE, et al. Identification of motifs for cell adhesion within the repeated domains of transforming growth factor-beta-induced gene, betaig-h3. *J Biol Chem.* 2000; 275(40):30907–30915. [PubMed: 10906123]
122. Ohno S, et al. RGD-CAP ((beta)ig-h3) enhances the spreading of chondrocytes and fibroblasts via integrin alpha(1)beta(1). *Biochim Biophys Acta.* 1999;1451(1): 196–205. [PubMed: 10446401]
123. Rabinowitz YS, Dong L, Wistow G. Gene expression profile studies of human keratoconus cornea for NEIBank: a novel cornea-expressed gene and the absence of transcripts for aquaporin 5. *Invest Ophthalmol Vis Sci.* 2005;46(4):1239–1246. [PubMed: 15790884]
124. Guan T, et al. The point mutation and polymorphism in keratoconus candidate gene TGFBI in Chinese population. *Gene.* 2012;503(1):137–139. [PubMed: 22575726]
125. Karolak JA, et al. Molecular screening of keratoconus susceptibility sequence variants in VSX1, TGFBI, DOCK9, STK24, and IPO5 genes in polish patients and novel TGFBI variant identification. *Ophthalmic Genet.* 2016;37(1):37–43. [PubMed: 24940934]
126. Takacs L, et al. Expression of betaig-h3 is lower than normal in keratoconus corneas but increases with scarring. *Cornea.* 1999;18(5):599–605. [PubMed: 10487436]
127. Group TDRSR. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. *Ophthalmology.* 1981;88(7):583–600. [PubMed: 7196564]
128. Wang M, et al. TGFBI gene transcript is transforming growth factor-beta1- responsive and cell density-dependent in a human corneal epithelial cell line. *Ophthalmic Genet.* 2002;23(4):237–245. [PubMed: 12567266]
129. Han B, et al. TGFBI (β IG-H3) is a diabetes-risk gene based on mouse and human genetic studies. *Hum Mol Genet.* 2014;23(17):4597–4611. [PubMed: 24728038]
130. Billings PC, et al. Extracellular matrix and nuclear localization of beta ig-h3 in human bladder smooth muscle and fibroblast cells. *J Cell Biochem.* 2000;79(2): 261–273. [PubMed: 10967553]
131. Park SW, et al. Beta ig-h3 promotes renal proximal tubular epithelial cell adhesion, migration and proliferation through the interaction with alpha3beta1 integrin. *Exp Mol Med.* 2004;36(3):211–219. [PubMed: 15272232]
132. Lee SH, et al. Expression of TGF-beta-induced matrix protein betaig-h3 is up-regulated in the diabetic rat kidney and human proximal tubular epithelial cells treated with high glucose. *Kidney Int.* 2003;64(3):1012–1021. [PubMed: 12911551]
133. Phillips AO, et al. Exposure of Human Renal Proximal Tubular Cells to Glucose Leads to Accumulation of Type IV Collagen and Fibronectin by Decreased Degradation. 52. 1997: 973–984, 4.
134. Ziyadeh FN. Role of transforming growth factor-beta in diabetic glomerulosclerosis and renal hypertrophy. *J Kidney Int Suppl.* 1995;51:S34–S36.
135. Ziyadeh FN, et al. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. *J Clin Invest.* 1994;93(2):536–542. [PubMed: 8113392]

136. Lane PH, et al. Renal Interstitial Expansion in Insulin-dependent Diabetes Mellitus. 43. 1993;661–667, 3.
137. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. *Am J Kidney Dis.* 1992;20(1):1–17. [PubMed: 1621674]
138. Munier FL, et al. BIGH3 mutation spectrum in corneal dystrophies. *Invest Ophthalmol Vis Sci.* 2002;43(4):949–954. [PubMed: 11923233]
139. Aldave AJ, et al. Posterior polymorphous corneal dystrophy is associated with TCF8 gene mutations and abdominal hernia. *Am J Med Genet.* 2007;143a(21):2549–2556. [PubMed: 17935237]
140. Krafchak CM, et al. Mutations in TCF8 cause posterior polymorphous corneal dystrophy and ectopic expression of COL4A3 by corneal endothelial cells. *Am J Hum Genet.* 2005;77(5):694–708. [PubMed: 16252232]
141. Terraz C, et al. Delta Ef1 binds to a far upstream sequence of the mouse pro-alpha 1(I) collagen gene and represses its expression in osteoblasts. *J Biol Chem.* 2001; 276(40):37011–37019. [PubMed: 11473112]
142. Vandewalle C, Van Roy F, Berx G. The role of the ZEB family of transcription factors in development and disease. *Cell Mol Life Sci.* 2009;66(5):773–787. [PubMed: 19011757]
143. Frisch SM. E1a induces the expression of epithelial characteristics. *J Cell Biol.* 1994; 127(4):1085–1096. [PubMed: 7525602]
144. Grootclaes ML, Frisch SM. Evidence for a function of CtBP in epithelial gene regulation and anoikis. *Oncogene.* 2000;19(33):3823–3828. [PubMed: 10949939]
145. Chiu L, et al. The ERK–ZEB1 Pathway Mediates Epithelial–Mesenchymal Transition in Pemetrexed Resistant Lung Cancer Cells with Suppression by vinca Alkaloids. 36. 2017: 242–253, 2.
146. Liu Y, et al. Notch signaling controls the differentiation of transporting epithelia and multiciliated cells in the zebrafish pronephros. *Development.* 2007;134(6): 1111–1122. [PubMed: 17287248]
147. Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. *Cell Cycle.* 2015;14(4):481–487. [PubMed: 25607528]
148. Postigo AA. Opposing functions of ZEB proteins in the regulation of the TGFbeta/ BMP signaling pathway. *EMBO J.* 2003;22(10):2443–2452. [PubMed: 12743038]
149. Liskova P, et al. Novel mutations in the ZEB1 gene identified in Czech and British patients with posterior polymorphous corneal dystrophy. *Hum Mutat.* 2007;28(6): 638.
150. Mehta JS, et al. Analysis of the posterior polymorphous corneal dystrophy 3 gene, TCF8, in late-onset Fuchs endothelial corneal dystrophy. *Invest Ophthalmol Vis Sci.* 2008;49(1):184–188. [PubMed: 18172091]
151. Riazuddin SA, et al. Missense mutations in TCF8 cause late-onset Fuchs corneal dystrophy and interact with FCD4 on chromosome 9p. *Am J Hum Genet.* 2010;86(1): 45–53. [PubMed: 20036349]
152. Lechner J, et al. Mutational spectrum of the ZEB1 gene in corneal dystrophies supports a genotype–phenotype correlation. *Investigative Ophthalmology & Visual Science.* 2013;54(5):3215–3223. [PubMed: 23599324]
153. Stachs O, et al. [The extracellular matrix structure in keratoconus]. *Ophthalmologe.* 2004;101(4):384–389. [PubMed: 15067420]
154. Mazzotta C, et al. First identification of a triple corneal dystrophy association: keratoconus, epithelial basement membrane corneal dystrophy and fuchs' endothelial corneal dystrophy. *Case Rep Ophthalmol.* 2014;5(3):281–288. [PubMed: 25408666]
155. Singh K, et al. Cutaneous epithelial to mesenchymal transition activator ZEB1 regulates wound angiogenesis and closure in a glycemic status-dependent manner. *Diabetes.* 2019;68(11):2175–2190. [PubMed: 31439646]
156. Pankow J, et al. Circulating Cellular Adhesion Molecules and Risk of Diabetes: The Multi-Ethnic Study of Atherosclerosis (MESA). 33. 2016:985–991, 7.
157. Liu C, Lin J. Long noncoding RNA ZEB1-AS1 acts as an oncogene in osteosarcoma by epigenetically activating ZEB1. *Am J Transl Res.* 2016;8(10):4095–4105. [PubMed: 27829995]

158. Meng Q, et al. lncRNA ZEB1-AS1 inhibits high glucose-induced EMT and fibrogenesis by regulating the miR-216a-5p/BMP7 axis in diabetic nephropathy. *Braz J Med Biol Res.* 2020;53(4):e9288. [PubMed: 32294702]
159. Loeffler I, Wolf G. Epithelial-to-Mesenchymal transition in diabetic nephropathy: fact or fiction? *Cells.* 2015;4(4):631–652. [PubMed: 26473930]
160. Sun J, et al. Role of epigenetic histone modifications in diabetic kidney disease involving renal fibrosis. *J Diabetes Res.* 2017;2017:7242384. [PubMed: 28695133]
161. Wang J, et al. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy. *Mol Ther Nucleic Acids.* 2018;12:741–750. [PubMed: 30121551]
162. Luotola K, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. *J Intern Med.* 2011;269(3):322–332. [PubMed: 21205020]
163. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. *Nat Rev Mol Cell Biol.* 2007;8(3):221–233. [PubMed: 17318226]
164. di Martino E, Ali M, Inglehearn CF. Matrix metalloproteinases in keratoconus – too much of a good thing? *Exp Eye Res.* 2019;182:137–143. [PubMed: 30910610]
165. Parks WC, Wilson CL, Lopez-Boado YS Matrix metalloproteinases as modulators of inflammation and innate immunity. *Nat Rev Immunol.* 2004;4(8):617–629. [PubMed: 15286728]
166. Balasubramanian SA, et al. Proteases, proteolysis and inflammatory molecules in the tears of people with keratoconus. *Acta Ophthalmol.* 2012;90(4):e303–e309. [PubMed: 22413749]
167. Smith V, Easty D. Matrix metalloproteinase 2: involvement in keratoconus. *Eur J Ophthalmol.* 2000;10(3):215–226. [PubMed: 11071029]
168. Lema I, Duran JA. Inflammatory molecules in the tears of patients with keratoconus. *Ophthalmology.* 2005;112(4):654–659. [PubMed: 15808258]
169. Lema I, et al. Subclinical keratoconus and inflammatory molecules from tears. *Br J Ophthalmol.* 2009;93(6):820–824. [PubMed: 19304583]
170. Shetty R, et al. Elevated expression of matrix metalloproteinase-9 and inflammatory cytokines in keratoconus patients is inhibited by cyclosporine A. *Investigative Ophthalmology & Visual Science.* 2015;56(2):738–750. [PubMed: 25648341]
171. Pahuja N, et al. Differential molecular expression of extracellular matrix and inflammatory genes at the corneal cone apex drives focal weakening in keratoconus. *Investigative Ophthalmology & Visual Science.* 2016;57(13):5372–5382. [PubMed: 27732724]
172. Sobrino T, et al. Higher Expression of Toll-like Receptors 2 and 4 in Blood Cells of Keratoconus Patients. *7.* 2017:1–7, 1.
173. Farina AR, Mackay AR. Gelatinase B/MMP-9 in tumour pathogenesis and progression. *Cancers.* 2014;6(1):240–296. [PubMed: 24473089]
174. Brown D, et al. Keratoconus corneas: increased gelatinolytic activity appears after modification of inhibitors. *Curr Eye Res.* 1993;12(6):571–581. [PubMed: 8359032]
175. Lee JE, et al. Evaluation of differentially expressed genes identified in keratoconus. *Mol Vis.* 2009;15:2480–2487. [PubMed: 19956410]
176. Abdullah OA, et al. Role of extracellular matrix remodelling gene SNPs in keratoconus. *Br J Biomed Sci.* 2020;77(1):13–18. [PubMed: 31397194]
177. Saravani R, et al. Correlation between the COL4A3, MMP-9, and TIMP-1 polymorphisms and risk of keratoconus. *Jpn J Ophthalmol.* 2017;61(3):218–222. [PubMed: 28197741]
178. Hardcastle AJ, et al. Genomic organization of the human TIMP-1 gene. Investigation of a causative role in the pathogenesis of X-linked retinitis pigmentosa 2. *Invest Ophthalmol Vis Sci.* 1997;38(9):1893–1896. [PubMed: 9286280]
179. Death AK, et al. High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. *Atherosclerosis.* 2003; 168(2):263–269. [PubMed: 12801609]
180. Takahashi H, et al. Matrix metalloproteinase activity is enhanced during corneal wound repair in high glucose condition. *Curr Eye Res.* 2000;21(2):608–615. [PubMed: 11148597]

181. Iyengar MF, et al. Tear biomarkers and corneal sensitivity as an indicator of neuropathy in type 2 diabetes. *Diabetes Res Clin Pract.* 2020;163:108143. [PubMed: 32283127]
182. Symeonidis C, et al. Matrix metalloproteinase (MMP-2, -9) and tissue inhibitor (TIMP-1, -2) activity in tear samples of pediatric type 1 diabetic patients: MMPs in tear samples from type 1 diabetes. *Graefes Arch Clin Exp Ophthalmol.* 2013;251(3): 741–749. [PubMed: 23254483]
183. Ahluwalia TS, et al. Common variants of inflammatory cytokine genes are associated with risk of nephropathy in type 2 diabetes among Asian Indians. *PloS One.* 2009;4(4):e5168. [PubMed: 19357773]
184. Nazir N, et al. Meta-analysis of diabetic nephropathy associated genetic variants in inflammation and angiogenesis involved in different biochemical pathways. *BMC Med Genet.* 2014;15:103. [PubMed: 25280384]
185. Saravani S, et al. Association of COL4A3 (rs55703767), MMP-9 (rs17576) and TIMP-1 (rs6609533) gene polymorphisms with susceptibility to type 2 diabetes. *Biomed Rep.* 2017;6(3):329–334. [PubMed: 28451395]
186. Lee RC, Feinbaum RL, Ambros V. The *C. elegans* heterochronic gene *lin-4* encodes small RNAs with antisense complementarity to *lin-14*. *Cell.* 1993;75(5):843–854. [PubMed: 8252621]
187. Hughes AE, et al. Mutation altering the miR-184 seed region causes familial keratoconus with cataract. *Am J Hum Genet.* 2011;89(5):628–633. [PubMed: 21996275]
188. Karali M, et al. miRNeYE: a microRNA expression atlas of the mouse eye. *BMC Genom.* 2010;11:715.
189. Ryan DG, Oliveira-Fernandes M, Lavker RM. MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. *Mol Vis.* 2006;12:1175–1184. [PubMed: 17102797]
190. Yu J, et al. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. *Proc Natl Acad Sci U S A.* 2008;105(49):19300–19305. [PubMed: 19033458]
191. Farzadfard A, et al. Screening for MIR184 mutations in Iranian patients with keratoconus. *J Ophthalmic Vis Res.* 2016;11(1):3–7. [PubMed: 27195078]
192. Shalom-Feuerstein R, et al. Pluripotent stem cell model reveals essential roles for miR-450b-5p and miR-184 in embryonic corneal lineage specification. *Stem Cell.* 2012;30(5):898–909.
193. Iliff BW, Riazuddin SA, Gottsch JD. A single-base substitution in the seed region of miR-184 causes EDICT syndrome. *Invest Ophthalmol Vis Sci.* 2012;53(1):348–353. [PubMed: 22131394]
194. Bykhovskaya Y, et al. C.57 C > T Mutation in MIR 184 is Responsible for congenital Cataracts and corneal Abnormalities in a five-generation Family from galicia, Spain. *Ophthalmic Genet.* 2015;36(3):244–247. [PubMed: 24138095]
195. Çag ıl N, et al. Lack of MIR143, MIR145, MIR184, MIR1224, and MIR29b1 mutations in keratoconus pathogenesis. *Turk J Med Sci.* 2017;47(5):1669–1671. [PubMed: 29152952]
196. Abu-Amero KK, et al. Screening of the seed region of MIR184 in keratoconus patients from Saudi Arabia. *BioMed Res Int.* 2015;2015:604508. [PubMed: 26380287]
197. Martinez-Sanchez A, Rutter GA, Latreille M. MiRNAs in β -cell development, identity, and disease. *Front Genet.* 2016;7:226. [PubMed: 28123396]
198. Martinez-Sanchez A, et al. MiR-184 expression is regulated by AMPK in pancreatic islets. *Faseb j.* 2018;32(5):2587–2600. [PubMed: 29269398]
199. Nesca V, et al. Identification of particular groups of microRNAs that positively or negatively impact on beta cell function in obese models of type 2 diabetes. *Diabetologia.* 2013;56(10):2203–2212. [PubMed: 23842730]
200. Tattikota SG, et al. Argonaute2 mediates compensatory expansion of the pancreatic β cell. *Cell Metabol.* 2014;19(1):122–134.
201. Tattikota SG, et al. miR-184 regulates pancreatic β -cell function according to glucose metabolism. *J Biol Chem.* 2015;290(33):20284–20294. [PubMed: 26152724]
202. Jun AS, et al. Subnormal cytokine profile in the tear fluid of keratoconus patients. *PloS One.* 2011;6(1), e16437. [PubMed: 21298010]
203. Fabre EJ, et al. Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus. *Curr Eye Res.* 1991;10(7):585–592. [PubMed: 1914496]

204. Efron N, Hollingsworth JG. New perspectives on keratoconus as revealed by corneal confocal microscopy. *Clin Exp Optom.* 2008;91(1):34–55. [PubMed: 18045250]
205. Behndig A, et al. Superoxide dismutase isoenzymes in the normal and diseased human cornea. *Invest Ophthalmol Vis Sci.* 2001;42(10):2293–2296. [PubMed: 11527942]
206. Buddi R, et al. Evidence of oxidative stress in human corneal diseases. *J Histochem Cytochem.* 2002;50(3):341–351. [PubMed: 11850437]
207. Joseph R, Srivastava OP, Pfister RR. Differential epithelial and stromal protein profiles in keratoconus and normal human corneas. *Exp Eye Res.* 2011;92(4): 282–298. [PubMed: 21281627]
208. Gondhowiardjo TD, van Haeringen NJJC. Corneal Aldehyde Dehydrogenase, Glutathione Reductase, and Glutathione S-Transferase in Pathologic Corneas. 12. 1993: 310–314, 4.
209. Atilano SR, et al. Accumulation of Mitochondrial DNA Damage in Keratoconus Corneas. 46. 2005:1256–1263, 4.
210. Chwa M, et al. Increased Stress-Induced Generation of Reactive Oxygen Species and Apoptosis in Human Keratoconus Fibroblasts. 47. 2006:1902–1910, 5.
211. Kenney MC, Brown DJ, Rajeev B. Everett Kinsey lecture. The elusive causes of keratoconus: a working hypothesis. *CLAO J.* 2000;26(1):10–13. [PubMed: 10656302]
212. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. *Ther Adv Med Oncol.* 2011;3(1 Suppl):S7–s19. [PubMed: 22128289]
213. Spix JK, et al. Hepatocyte growth factor induces epithelial cell motility through transactivation of the epidermal growth factor receptor. *Exp Cell Res.* 2007;313(15): 3319–3325. [PubMed: 17643426]
214. Wilson SE, et al. Hepatocyte growth factor, keratinocyte growth factor, their receptors, fibroblast growth factor receptor-2, and the cells of the cornea. *Invest Ophthalmol Vis Sci.* 1993;34(8):2544–2561. [PubMed: 8392040]
215. Li Q, et al. Hepatocyte growth factor and hepatocyte growth factor receptor in the lacrimal gland, tears, and cornea. *Invest Ophthalmol Vis Sci.* 1996;37(5):727–739. [PubMed: 8603858]
216. Wilson SE, Liang Q, Kim WJ. Lacrimal gland HGF, KGF, and EGF mRNA levels increase after corneal epithelial wounding. *Invest Ophthalmol Vis Sci.* 1999;40(10): 2185–2190. [PubMed: 10476782]
217. Burdon KP, et al. Association of polymorphisms in the hepatocyte growth factor gene promoter with keratoconus. *Investigative Ophthalmology & Visual Science.* 2011; 52(11):8514–8519. [PubMed: 22003120]
218. Sahebjada S, et al. Association of the hepatocyte growth factor gene with keratoconus in an Australian population. *PloS One.* 2014;9(1), e84067. [PubMed: 24416191]
219. Huang YY, Neuhauss SC. The optokinetic response in zebrafish and its applications. *Front Biosci.* 2008;13:1899–1916. [PubMed: 17981678]
220. Saghizadeh M, et al. Proteinase and growth factor alterations revealed by gene microarray analysis of human diabetic corneas. *Invest Ophthalmol Vis Sci.* 2005; 46(10):3604–3615. [PubMed: 16186340]
221. Chen WL, et al. In vivo confocal microscopic findings of corneal wound healing after corneal epithelial debridement in diabetic vitrectomy. *Ophthalmology.* 2009; 116(6):1038–1047. [PubMed: 19394702]
222. Kabosova A, et al. Human diabetic corneas preserve wound healing, basement membrane, integrin and MMP-10 differences from normal corneas in organ culture. *Exp Eye Res.* 2003;77(2):211–217. [PubMed: 12873452]
223. Saghizadeh M, et al. Normalization of wound healing and diabetic markers in organ cultured human diabetic corneas by adenoviral delivery of c-met gene. *Investigative Ophthalmology & Visual Science.* 2010;51(4):1970–1980.
224. Oliveira AG, et al. The role of hepatocyte growth factor (HGF) in insulin resistance and diabetes. *Front Endocrinol.* 2018;9:503.
225. Zatz M, Starling A. Calpains and disease. *N Engl J Med.* 2005;352(23):2413–2423. [PubMed: 15944426]

226. Li X, et al. An association between the calpastatin (CAST) gene and keratoconus. *Cornea*. 2013;32(5):696–701. [PubMed: 23449483]
227. Shearer TR, et al. Calpain and calpastatin in rabbit corneal epithelium. *Curr Eye Res*. 1990;9(1):39–44. [PubMed: 2311414]
228. Persson H, Kawashima S, Karlsson JO. Immunohistochemical localization of calpains and calpastatin in the rabbit eye. *Brain Res*. 1993;611(2):272–278. [PubMed: 8334520]
229. Zhang J, et al. Evaluating the association between calpastatin (CAST) gene and keratoconus in the Han Chinese population. *Gene*. 2018;653:10–13. [PubMed: 29428799]
230. Chen B, et al. Inhibition of calpain reduces oxidative stress and attenuates endothelial dysfunction in diabetes. *Cardiovasc Diabetol*. 2014;13:88. [PubMed: 24886224]
231. Ohara T, Sussman KE, Draznin B. Effect of diabetes on cytosolic free Ca²⁺ and Na⁺(⁺)-ATPase in rat aorta. *Diabetes*. 1991;40(11):1560–1563. [PubMed: 1657671]
232. Stalker TJ, Gong Y, Scalia R. The calcium-dependent protease calpain causes endothelial dysfunction in type 2 diabetes. *Diabetes*. 2005;54(4):1132–1140. [PubMed: 15793253]
233. Wan S, et al. Na⁺/H exchanger is required for hyperglycaemia-induced endothelial dysfunction via calcium-dependent calpain. *Cardiovasc Res*. 2008;80(2): 255–262. [PubMed: 18591204]
234. Bryk D, et al. Trans fatty acids induce a proinflammatory response in endothelial cells through ROS-dependent nuclear factor- κ B activation. *J Physiol Pharmacol*. 2011;62(2):229–238. [PubMed: 21673371]
235. Cifarelli V, et al. C-peptide reduces high-glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation in human aortic endothelial cells. *Diabetologia*. 2011;54(10):2702–2712. [PubMed: 21773684]
236. Randriamboavonjy V, et al. Calpain 1 cleaves and inactivates prostacyclin synthase in mesenteric arteries from diabetic mice. *Basic Res Cardiol*. 2017;112(1):10. [PubMed: 28013348]
237. Arnal E, et al. Oxidative stress in keratoconus? *Invest Ophthalmol Vis Sci*. 2011; 52(12):8592–8597. [PubMed: 21969298]
238. Moschos MM, et al. Polymorphism analysis of VSX1 and SOD1 genes in Greek patients with keratoconus. *Ophthalmic Genet*. 2015;36(3):213–217. [PubMed: 24099280]
239. Udar N, et al. SOD1: a candidate gene for keratoconus. *Invest Ophthalmol Vis Sci*. 2006;47(8):3345–3351. [PubMed: 16877401]
240. Gadelha DNB, et al. Screening for novel LOX and SOD1 variants in keratoconus patients from Brazil. *J Ophthalmic Vis Res*. 2020;15(2):138–148. [PubMed: 32308947]
241. Atilano SR, et al. Corneal oxidative damage in keratoconus cells due to decreased oxidant elimination from modified expression levels of SOD enzymes, PRDX6, SCARA3, CPSF3, and FOXM1. *J Ophthalmic Vis Res*. 2019;14(1):62–70. [PubMed: 30820289]
242. Al-Muammar AM, et al. Analysis of the SOD1 gene in keratoconus patients from Saudi Arabia. *Ophthalmic Genet*. 2015;36(4):373–375. [PubMed: 24547927]
243. Gajecka M, et al. Localization of a gene for keratoconus to a 5.6-mb interval on 13q32. *Investigative Ophthalmology & Visual Science*. 2009;50(4):1531–1539. [PubMed: 19011015]
244. Stabuc-Silih M, et al. Absence of pathogenic mutations in VSX1 and SOD1 genes in patients with keratoconus. *Cornea*. 2010;29(2):172–176. [PubMed: 20023586]
245. De Bonis P, et al. Mutational screening of VSX1, SPARC, SOD1, LOX, and TIMP3 in keratoconus. *Mol Vis*. 2011;17:2482–2494. [PubMed: 21976959]
246. Saeed-Rad S, et al. Mutation analysis of VSX1 and SOD1 in Iranian patients with keratoconus. *Mol Vis*. 2011;17:3128–3136. [PubMed: 22171159]
247. van Zundert B, Brown RH Jr. Silencing strategies for therapy of SOD1-mediated ALS. *Neurosci Lett*. 2017;636:32–39. [PubMed: 27507699]
248. Logroscino G. Motor neuron disease: are diabetes and amyotrophic lateral sclerosis related? *Nat Rev Neurol*. 2015;11(9):488–490. [PubMed: 26281962]
249. Flekac M, et al. Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. *BMC Med Genet*. 2008;9:30. [PubMed: 18423055]
250. Haldar SR, et al. Oxidative stress-related genes in type 2 diabetes: association analysis and their clinical impact. *Biochem Genet*. 2015;53(4–6):93–119. [PubMed: 25991559]

251. Mohammadi K, et al. Allelic variations in superoxide dismutase-1 (SOD1) gene are associated with increased risk of diabetic nephropathy in type 1 diabetic subjects. *Mol Genet Metabol.* 2011;104(4):654–660.
252. Neves AL, et al. Allelic variations in superoxide dismutase-1 (SOD1) gene and renal and cardiovascular morbidity and mortality in type 2 diabetic subjects. *Mol Genet Metabol.* 2012;106(3):359–365.
253. Panduru NM, et al. . Association of 35A/C (intron3/exon3) polymorphism in SOD1-gene with diabetic nephropathy in type 1 diabetes. *Rom J Morphol Embryol.* 2010;51(1):37–41. [PubMed: 20191117]
254. Yin J, et al. Interactions between plasma copper concentrations and SOD1 gene polymorphism for impaired glucose regulation and type 2 diabetes. *Redox Biol.* 2019;24:101172.
255. Kay AM, Simpson CL, Stewart JA Jr. The role of AGE/RAGE signaling in diabetes- mediated vascular calcification. *J Diabetes Res.* 2016;2016:6809703.
256. Liu X, et al. PEDF attenuates ocular surface damage in diabetic mice model through its antioxidant properties. *Curr Eye Res.* 2020:1–7.
257. Mikami T, et al. Interleukin 1 beta promoter polymorphism is associated with keratoconus in a Japanese population. *Mol Vis.* 2013;19:845–851. [PubMed: 23592922]
258. Strissel KJ, Rinehart WB, Fini ME. Regulation of paracrine cytokine balance controlling collagenase synthesis by corneal cells. *Investigative Ophthalmology & Visual Science.* 1997;38(2):546–552. [PubMed: 9040490]
259. West-Mays JA, et al. Repair phenotype in corneal fibroblasts is controlled by an interleukin-1 alpha autocrine feedback loop. *Investigative Ophthalmology & Visual Science.* 1997;38(7):1367–1379. [PubMed: 9191600]
260. Kim WJ, et al. Keratocyte apoptosis associated with keratoconus. *Exp Eye Res.* 1999; 69(5):475–481. [PubMed: 10548467]
261. Wilson SE, et al. Epithelial injury induces keratocyte apoptosis: hypothesized role for the interleukin-1 system in the modulation of corneal tissue organization and wound healing. *Exp Eye Res.* 1996;62(4):325–327. [PubMed: 8795451]
262. Wang Y, et al. Association of interleukin-1 gene single nucleotide polymorphisms with keratoconus in Chinese han population. *Curr Eye Res.* 2016;41(5):630–635. [PubMed: 26200829]
263. Kim SH, et al. Association of –31T>C and –511 C>T polymorphisms in the interleukin 1 beta (IL1B) promoter in Korean keratoconus patients. *Mol Vis.* 2008; 14:2109–2116. [PubMed: 19043479]
264. Palamar M, et al. Relationship between IL1 β –511C>T and ILRN VNTR polymorphisms and keratoconus. *Cornea.* 2014;33(2):145–147. [PubMed: 24322806]
265. Banerjee M, Saxena M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. *Clin Chim Acta.* 2012;413(15–16):1163–1170. [PubMed: 22521751]
266. Interleukin Helqvist S. 1 beta-mediated destruction of pancreatic beta-cells in vitro. A model of beta-cell destruction in insulin-dependent diabetes mellitus? *Dan Med Bull.* 1994;41(2):151–166. [PubMed: 8039431]
267. Mandrup-Poulsen T, et al. Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic beta-cell destruction in insulin-dependent diabetes mellitus. *Cytokine.* 1993;5(3):185–191. [PubMed: 8218929]
268. Yan C, et al. Targeting imbalance between IL-1 β and IL-1 receptor antagonist ameliorates delayed epithelium wound healing in diabetic mouse corneas. *Am J Pathol.* 2016;186(6):1466–1480. [PubMed: 27109611]
269. Tripathi A, Sodhi A. Prolactin-induced production of cytokines in macrophages in vitro involves JAK/STAT and JNK MAPK pathways. *Int Immunol.* 2008;20(3): 327–336. [PubMed: 18187558]
270. Sharif R, et al. Prolactin-Induced Protein is a novel biomarker for Keratoconus. *Exp Eye Res.* 2019;179:55–63. [PubMed: 30393162]
271. Sharif R, et al. Pathogenesis of Keratoconus: the intriguing therapeutic potential of Prolactin-inducible protein. *Prog Retin Eye Res.* 2018;67:150–167. [PubMed: 29758268]

272. Chambers D, Mason I. Expression of sprouty2 during early development of the chick embryo is coincident with known sites of FGF signalling. *Mech Dev.* 2000;91(1–2): 361–364. [PubMed: 10704865]
273. Faedo A, Borello U, Rubenstein JL. Repression of Fgf signaling by sprouty1–2 regulates cortical patterning in two distinct regions and times. *J Neurosci.* 2010; 30(11):4015–4023. [PubMed: 20237272]
274. Minowada G, et al. Vertebrate Sprouty genes are induced by FGF signaling and can cause chondrodysplasia when overexpressed. *Development.* 1999;126(20): 4465–4475. [PubMed: 10498682]
275. Basson MA, et al. Sprouty1 is a critical regulator of GDNF/RET-mediated kidney induction. *Dev Cell.* 2005;8(2):229–239. [PubMed: 15691764]
276. Shim K, et al. Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. *Dev Cell.* 2005;8(4): 553–564. [PubMed: 15809037]
277. Ding W, Warburton DJB. Down-regulation of Sprouty2 via p38 MAPK plays a key role in the induction of cellular apoptosis by tumor necrosis factor- α . *b.r. communications.* 2008;375(3):460–464.
278. Kuracha MR, et al. Spry1 and Spry2 are necessary for lens vesicle separation and corneal differentiation. *Invest Ophthalmol Vis Sci.* 2011;52(9):6887–6897. [PubMed: 21743007]
279. Kuracha MR, et al. Spry1 and Spry2 are necessary for eyelid closure. *Dev Biol.* 2013; 383(2):227–238. [PubMed: 24055172]
280. Imamura M, et al. Genetic variants at CDC123/CAMK1D and SPRY2 are associated with susceptibility to type 2 diabetes in the Japanese population. *Diabetologia.* 2011;54(12):3071–3077. [PubMed: 21909839]
281. Shu XO, et al. Identification of new genetic risk variants for type 2 diabetes. *PLoS Genet.* 2010;6(9), e1001127.
282. Cook NL, et al. CRISPR-Cas9-mediated knockout of SPRY2 in human hepatocytes leads to increased glucose uptake and lipid droplet accumulation. *BMC Endocr Disord.* 2019;19(1):115. [PubMed: 31664995]
283. Stabuc-Silih M, et al. Polymorphisms in COL4A3 and COL4A4 genes associated with keratoconus. *Mol Vis.* 2009;15:2848–2860. [PubMed: 20029656]
284. Ljubimov AV, et al. Human corneal basement membrane heterogeneity: topographical differences in the expression of type IV collagen and laminin isoforms. *Lab Invest.* 1995;72(4):461–473. [PubMed: 7723285]
285. Lemmink HH, et al. The clinical spectrum of type IV collagen mutations. *Hum Mutat.* 1997;9(6):477–499. [PubMed: 9195222]
286. Bochet A, et al. [Gene expression in keratoconus. Initial results using DNA microarrays]. *Ophthalmologie.* 2003;100(7):545–549. [PubMed: 12920555]
287. Kokolakis NS, et al. Polymorphism analysis of COL4A3 and COL4A4 genes in Greek patients with keratoconus. *Ophthalmic Genet.* 2014;35(4):226–228. [PubMed: 25083577]
288. Mas Tur V, et al. A review of keratoconus: diagnosis, pathophysiology, and genetics. *Surv Ophthalmol.* 2017;62(6):770–783. [PubMed: 28688894]
289. Yagame M, et al. Differential distribution of type IV collagen chains in patients with diabetic nephropathy in non-insulin-dependent diabetes mellitus. *Nephron.* 1995; 70(1):42–48. [PubMed: 7617116]
290. Salem RM, et al. Genome-wide association study of diabetic kidney disease highlights biology involved in glomerular basement membrane collagen. *J Am Soc Nephrol.* 2019;30(10):2000–2016. [PubMed: 31537649]
291. Onochie OE, et al. The role of hypoxia in corneal extracellular matrix deposition and cell motility. *Anat Rec.* 2020;303(6):1703–1716.
292. Davies PD, et al. Aqueous humour glucose concentration in cataract patients and its effect on the lens. *Exp Eye Res.* 1984;39(5):605–609. [PubMed: 6519197]
293. Foulks GN, et al. Factors related to corneal epithelial complications after closed vitrectomy in diabetics. *Arch Ophthalmol.* 1979;97(6):1076–1078. [PubMed: 444136]

294. Kaji Y, et al. Advanced glycation end products in diabetic corneas. *Investigative Ophthalmology & Visual Science*. 2000;41(2):362–368. [PubMed: 10670463]
295. Goldstein AS, et al. The effects of diabetes mellitus on the corneal endothelium: a review. *Surv Ophthalmol*. 2020;65(4):438–450. [PubMed: 31926185]
296. Saini JS, Mittal S. In vivo assessment of corneal endothelial function in diabetes mellitus. *Arch Ophthalmol*. 1996;114(6):649–653. [PubMed: 8639073]
297. El-Agamy A, Alsubaie SJCO. Corneal Endothelium and Central Corneal Thickness Changes in Type 2 Diabetes Mellitus. 11. 2017:481.
298. Lee HK, Jung EH, Cho BJ. Epidemiological association between systemic diseases and keratoconus in a Korean population: a 10-year nationwide cohort study. *Cornea*. 2020;39(3):348–353. [PubMed: 31764280]
299. Hashemi H, et al. The prevalence and risk factors for keratoconus: a systematic review and meta-analysis. *Cornea*. 2020;39(2):263–270. [PubMed: 31498247]
300. Guzel B, et al. Corneal changes in diabetes mellitus. *Curr Diabetes Rev*. 2012;8(4): 294–302. [PubMed: 22587515]
301. Markoulli M, et al. The impact of diabetes on corneal nerve morphology and ocular surface integrity. *Ocul Surf*. 2018;16(1):45–57. [PubMed: 29113918]
302. Dogru M, Katakami C, Inoue M. Tear function and ocular surface changes in noninsulin-dependent diabetes mellitus. *Ophthalmology*. 2001;108(3):586–592. [PubMed: 11237914]
303. Inoue K, et al. Blinking and superficial punctate keratopathy in patients with diabetes mellitus. *Eye*. 2005;19(4):418–421. [PubMed: 15286669]
304. Miller DD, et al. Recurrent corneal erosion: a comprehensive review. *Clin Ophthalmol*. 2019;13:325–335. [PubMed: 30809089]
305. Valgaeren H, Koppen C, Van Camp G. A new perspective on the genetics of keratoconus: why have we not been more successful? *Ophthalmic Genet*. 2018;39(2): 158–174. [PubMed: 29111844]
306. Lontchi-Yimagou E, et al. Diabetes mellitus and inflammation. *Curr Diabetes Rep*. 2013;13(3):435–444.
307. Type Reinehr T. 2 diabetes mellitus in children and adolescents. *World J Diabetes*. 2013;4(6):270–281. [PubMed: 24379917]
308. Szczotka LB, Barr JT, Zadnik K. A summary of the findings from the collaborative longitudinal evaluation of keratoconus (CLEK) study. CLEK study group. *Optometry*. 2001;72(9):574–584. [PubMed: 11575695]
309. Zadnik K, et al. Baseline findings in the collaborative longitudinal evaluation of keratoconus (CLEK) study. *Invest Ophthalmol Vis Sci*. 1998;39(13):2537–2546. [PubMed: 9856763]
310. Wheeler J, et al. The genetics of keratoconus: a review. *Reprod Syst Sex Disord*. 2012;(Suppl 6).
311. Lechner J, et al. Mutational analysis of MIR184 in sporadic keratoconus and myopia. *Invest Ophthalmol Vis Sci*. 2013;54(8):5266–5272. [PubMed: 23833072]




Fig. 1. In KC and DM, several overlapping mechanisms may contribute to the discussed pathology, including alterations in corneal biomechanics and collagen crosslinking, alterations in ECM composition and proteolytic activity, as well as increased inflammation and oxidative stress.

List of human studies evaluating the relationship between keratoconus and diabetes (adapted and modified from 26).

Table 1

Study	Study size	Design	Population Characteristics	Findings	Association
13	KC patients (n=571) Non-KC controls (n=571)	Retrospective case-control study	<ul style="list-style-type: none"> - German population - Hospital/clinic-based - Ethnicity unspecified - Age range: 20–40 yo; Mean age KC: 28.86 ± 5.79 years. Mean age control: 29.45 ± 5.75 	T2DM showed a protective effect against KC development (odds ratio = 0.2195)	Inverse association of KC development with DM
14	KC patients without DM (n=269) KC patients with DM (n=26)	Retrospective cross-sectional study	<ul style="list-style-type: none"> - United States population - Wilmer Eye Institute; Hospital/ clinic-based - Ethnicity: White, Black, Other - Age range: 14–80 yo; Mean age 42.7 ± 13.4 	T2DM showed a protective effect against more severe KC (odds ratio = 0.2); No difference in DM prevalence in KC population	Inverse association of DM with KC severity
17	KC patients (n=1383) non-KC controls (n=1383)	Retrospective case-control study	<ul style="list-style-type: none"> - Iranian population - Farabi Eye Hospital; Hospital/ clinic-based - Ethnicity unspecified - Age range: 18–49 yo. Mean age KC: 28.8 ± 5.3 years. Mean age control: 29.1 ± 5.8 years. 	T2DM showed a protective effect against KC development (odds ratio = 0.350)	Inverse association of KC development with DM
18	KC patients (n=16,053) non-KC controls (n=16,053)	Retrospective longitudinal cohort study	<ul style="list-style-type: none"> - United States population - Population-based - Multiple ethnicity (White, Black, Latino, Asian, Other) - All ages included; Mean age 40.4 ± 13.0 years (KC and matched controls) 	20% lower odds of KC development with uncomplicated DM; 52% lower odds of KC development with DM-associated organ failure	Inverse association of KC development with DM
19	KC patients (n=2679) non-KC controls (n=26,7900)	Retrospective longitudinal cohort study	<ul style="list-style-type: none"> - Danish population - Population-based - Ethnicity: European vs. Non-European - All ages included. Mean age: 38.2 ± 15.9 (KC and matched controls) 	No significant difference in DM prevalence in KC patients. Total DM odds ratio=1.03, T1DM odds ratio=0.87, T2DM odds ratio=1.07	No significant association between KC development and DM
298	KC patients (n=575) non-KC controls (n=2875)	Retrospective longitudinal cohort study	<ul style="list-style-type: none"> - Korean population - Population-based - Ethnicity unspecified - All ages included. Mean age: 31.1 ± 16.0 (KC and matched controls) 	No significant difference in DM prevalence in KC patients. Multivariate odds ratio=1.02	No significant association between KC development and DM
299	29 studies incorporating 50,358,341 subjects	Systematic review and meta-analysis	<ul style="list-style-type: none"> - Global population; 15 countries - Hospital/clinic/population based 	Odds of developing KC were 23% lower in T2DM, but relationship was not significant	No significant association between KC development and DM
22	KC patients (n=2051) non-KC controls (n=12,306)	Retrospective case-control study	<ul style="list-style-type: none"> - Netherlands population - Population-based, comparable socioeconomic distribution - Relative age group 10–40 years. Mean age KC and control: 30 ± 6.5. 	No significant association in KC and DM, with odds ratio 1.60 (0.89–2.89) and p-value 0.149.	No significant association between KC development and DM
20	KC patients (n=1377) non-KC controls (n=4131) AND T2DM KC patients (n=75) non-DM KC controls (n=225)	Retrospective case-control and Cross-sectional study	<ul style="list-style-type: none"> - United States population - Wills Eye Hospital Cornea Service; Hospital/clinic-based - Ethnicity unspecified 	Higher prevalence of T2DM in KC population compared to controls (6.75% and 4.84%, respectively); Higher severity of KC in DM patients (odds ratio = 2.691)	Positive association of KC development with T2DM

Study	Study size	Design	Population Characteristics	Findings	Association
21	KC patients (n=1552) non-KC controls (n=7,760)	Retrospective cohort study	<ul style="list-style-type: none"> - All ages included; Mean age KC: 44.64 ± 15.76 years. Mean age control: 45.06 ± 16.00 - South Korean population - Population-based - Ethnicity unspecified - All ages included. 	Higher prevalence of T2DM in KC population compared to controls (19.2% and 14.5%, respectively); Positive association of KC with DM (odds ratio = 1.35)	Positive association of KC development with DM

Table 2
List of genes that could mediate the potential correlation between keratoconus and diabetes.

Gene	Functions	CHR	KC/CCT effects	DM effects	References
Cornea biomechanics and collagen crosslinking					
<i>LOX</i>	Lysyl oxidase, participates in collagen crosslinking	5q23.2	Reduced LOX expression in corneal stroma and reduced activity in KC-derived corneal fibroblasts	Increased LOX expression and activity in retinal endothelial cells; unclear effect in DM cornea	33,45,47,58
<i>COL5A1</i>	Collagen type V, alpha-1 chain	9q34.2q34.3	COL5A1 haploinsufficiency results in corneal stroma thinning, reduced collagen fibers	Possible interaction between COL5A1 and HbA1c in DR study; no known direct effect on COL5A1 in cornea	65,66,72,81
ECM remodeling					
<i>FOXO1</i>	Transcription factor	13q14.1	SNP in FOXO1 linked to CCT; FOXO1 expression/activity unknown in cornea	FOXO1 linked to AGE-mediated disruption of autophagic flux and vascular endothelial cell autophagic apoptosis, role in cornea unknown	66,85,90
<i>SMAD3</i>	Transcription factor	15q22.23	SNP in SMAD3 linked to CCT; Increased pSMAD3 and increased TGFβ signaling in KC cells	SMAD3 linked to ECM remodeling in DN; role in cornea unclear	49,98,100,106
<i>TGFBI</i>	Transforming growth factor beta induced	5q31.1	SNP in TGFBI linked to KC with decreased levels of TGFBIp in KC cornea	Unknown effect in DM cornea, shown to be upregulated in response to high glucose and TGFβ in DM proximal tubules	124-126,132
<i>ZEB1</i>	Zinc finger transcription factor	10p11.22	Mutations in ZEB1 associated with KC and PPCD; possible genotype/phenotype correlation	Unknown effect in DM cornea, implicated in epithelial-to-mesenchymal transition under hyperglycemic conditions	152,154,155,158
<i>MMP-9</i>	Matrix metalloproteinase-9	20q11.2q13.1	Increased MMP-9 activity noted in tear sample with corresponding upregulation in MMP-9 mRNA; SNP identified in MMP-9	Increased MMP-9 activity in tears from DM patients; SNP identified in MMP-9 associated with T2DM susceptibility	170,173,176,181,185
<i>TIMP-1</i>	Tissue inhibitor of metalloproteinases-1	Xp11.23	Decreased TIMP-1 levels detected in KC patients, SNP in TIMP-1 associated with increased KC risk	Increased TIMP-1 levels in tears of pediatric T1DM patients, but overall role of TIMP-1 in DM remains inconclusive	83,178,182,185
<i>MIR184</i>	microRNA	15q22q25	Mutations in miR-184 implicated in KC pathogenesis, but extent of association with KC alone remains unclear	miR-184 expression decreased in pancreatic β cells in response to extracellular glucose; decreased in islet cells of T2DM patients	187,196,200,201,310,311
Inflammation and ROS production					
<i>HGF</i>	Hepatocyte growth factor	7q21.1	Increased HGF protein in KC corneal epithelium; increased HGF and c-Met mRNA in corneal wound healing	Increased HGF with decreased HGF receptor c-Met expression in DM cornea	3,214,217,220

Gene	Functions	CHR	KC/CCT effects	DM effects	References
<i>CAST</i>	Calpain/calpastatin, proteolytic degradation	5q15	SNP in CAST strongly linked to KC; CAST expression/activity unclear	High glucose induces calpain activity, increasing ROS production and vascular endothelial dysfunction; unknown effect in cornea	226,229,230
<i>SOD1</i>	Superoxide dismutase 1 cytoplasmic antioxidant enzyme	21q22.11	Deletion mutation in SOD1 in several cohorts; decreased SOD1 expression in KC corneal fibroblast cultures	Associated polymorphisms in SOD1 identified; decreased SOD1 expression in DM cornea with associated increase in RAGE	238-241,254,256
<i>IL1A/IL1B</i>	Interleukin 1alpha/beta, inflammatory cytokine	2q13	Increased IL-1 α expression in KC corneas, SNPs identified in IL1A and IL1B	Imbalance in IL-1 β to IL-1Ra in DM cornea, SNPs identified in IL1A, IL1B, and IL1RN in DM patients	119,162,203,262,268
Additional genes of interest					
<i>SPRY2</i>	Sprouty 2	13q31.1	SNP in SPRY2 linked to CCT and corneal epithelium proliferation; SPRY2 expression activity in KC cornea unknown	SNP near SPRY2 linked to increase DM susceptibility; unclear effect in SPRY2 cornea	49,278,280-282
<i>COL4A3, COL4A4</i>	Collagen type IV, alpha-3/4 chain, structural portion of corneal membranes	2q36.3	Alterations in collagen type IV reported in KC, but unclear if genetic polymorphisms play a role	Alterations in collagen type IV reported in DN and in the cornea under hypoxic conditions, unknown genetic association with DM cornea	48,283,290,291